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Abstract 
 Currently, two types of medications, cholinesterase inhibitors and N-methyl d-
aspartate (NMDA) receptor antagonists, are approved by the FDA for the treatment of 
cognitive dementia symptoms; however, there are no approved pharmacologic treatment 
options available for the management of mood and behavioral disturbances.  As a result, 
several types of psychotropic medications are used “off-label” to mitigate the often 
troublesome, non-cognitive symptoms of dementia.  This practice has come under 
considerable scrutiny following the 2005 and 2008 FDA black box warnings regarding 
the increased risk of stroke and death associated with the use of antipsychotics in elderly 
people with dementia. 
 Despite the associated risks, psychotropics are still prescribed to people with 
dementia.  The lack of safe, alternative medications highlights the need for non-
pharmaceutical interventions.  In order for future interventions to be effective, they must 
target modifiable medication risk factors.  Current research surrounding psychotropic 
medication use in people with dementia focuses on residents of nursing homes.  
Published work examining medication use among community-dwelling dementia patients 
is rare and none of the existing studies examine the role of informal caregivers.   
The purpose of this dissertation is to investigate a broad range of care recipient 
and caregiver characteristics as cross-sectional and longitudinal predictors of 
psychotropic medication both between and within racially and ethnically diverse 
populations of community-dwelling dementia patients and their informal caregivers. 
viii 
 
 Using data from the Resources for Enhancing Alzheimer’s Caregiver Health 
Trials, we found that caregiver and care recipient characteristics are important predictors 
of psychotropic medication use among community-dwelling dementia patients, and that 
the association between care recipient symptoms and medication decreases over time.  
Significant racial/ethnic disparities in psychotropic medication use between care 
recipients from three racial/ethnic groups were observed in our final study.  Within race 
analyses revealed significant associations between Hispanic/Latino caregiver social 
networks and care recipient psychotropic medication use.  No clear pattern was observed 
for other racial/ethnic groups.  Future public health efforts should focus on a 
multidisciplinary approach to dementia care where the knowledge and skills of persons 
trained in cultural competence and non-pharmaceutical interventions work together with 
physicians and caregivers to provide a safe alternative to psychotropic medication. 
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Chapter 1  
 
Introduction 
 
Dementia is a syndrome characterized by a progressive decline in cognitive 
function beyond what would be expected with normal aging.  It affects many areas of 
brain function including memory, language, problem solving and attention.  Currently, 
dementia is an irreversible, disabling, fatal disease for which there is no cure.  Although 
some people live well with dementia, for many patients and their families, dementia is a 
distressing disease.  Aside from problems with memory, other common symptoms 
include depression, delusions, hallucinations, restlessness, wandering, agitation, 
aggression, and other inappropriate behaviors.  Alzheimer’s disease, the most common 
form of dementia, has a considerable personal cost and has been described as a 
“prolonged and tragic illness that robs the affected patient of their individuality and 
dignity” (1). 
The impact of dementia on public health is also quite large and will continue to 
grow as the population ages.  In 2000, there were approximately 4.5 million individuals 
living with Alzheimer’s dementia in the United States.  The prevalence is expected to 
reach approximately 13.2 million by the year 2050, with a disproportionate burden of 
disease falling on women and minorities (2, 3).  A majority of dementia patients remain 
in the community and are cared for by relatives (4).  These informal caregivers are 
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responsible for managing a variety of troublesome symptoms including sleep 
disturbances, incontinence, changes in personality, psychiatric and behavioral 
disturbances, and declines in self-care (5).  Informal caregivers also provide a majority of 
the daily care that is required by an individual with dementia.  The estimated value of the 
services provided by informal caregivers of dementia patients is approximately $18 
billion annually (6). 
At present, there is no cure for dementia.  Treatment goals include slowing the 
rate of cognitive decline and mitigating mood and behavioral disturbances.  There are 
currently two types of medications approved by the Federal Food and Drug 
Administration (FDA) for the treatment of cognitive dementia symptoms.  These 
medications include cholinesterase inhibitors and N-methyl d-aspartate (NMDA) receptor 
antagonists.  Cholinesterase inhibitors work by preventing the degradation of the 
neurotransmitter acetylcholine, increasing cholinergic activity in the brain (7).  There are 
multiple cholinesterase inhibitor options available for individuals with dementia 
including galantamine and rivastigmine for mild and moderate dementia (8, 9), and 
donepezil, which is approved for use in individuals with severe dementia (10).  These 
medications are generally well-tolerated resulting in patient compliance and patient and 
caregiver acceptability (11, 12).  Tacrine, the first cholinesterase approved by the FDA to 
treat dementia, is still available; however, many patients experience severe adverse drug 
reactions at therapeutic doses, making newer cholinesterase inhibitors the preferred 
treatment option (13). 
The other class of approved anti-dementia medications includes NMDA receptor 
antagonists.  These medications block the effects of abnormal glutamate activity that lead 
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to neuronal cell death and cognitive dysfunction (14).  Memantine, approved for 
moderate to severe stages of dementia, is currently the only NMDA receptor antagonist 
available for the treatment of dementia.  It demonstrates moderate affinity binding and 
rapid blocking and unblocking kinetics, thus allowing enough physiologic activation of 
NMDA receptors required for learning and memory.  Memantine is well-tolerated and is 
not associated with serious adverse events (15). 
 In addition to approved anti-dementia medications, multiple psychotropic 
medications including anxiolytics, antipsychotics, antidepressants, and anticonvulsants 
are used to treat dementia.  These medications have not received a dementia indication 
and are used “off-label” to manage mood and behavioral symptoms.  Antipsychotics have 
received special attention in recent years due to the 2005 and 2008 FDA-mandated black 
box warning concerning the increased risk of stroke and death in elderly dementia 
patients (16-18); however, recent work has found that these drugs are the most popular 
class of therapeutics among dementia patients, ranking second only to 
acetylcholinesterase inhibitors (19). 
Other psychoactive medications used to treat mood and behavioral disturbances 
also have established risks.  For example, benzodiazepines, a class of anxiolytic 
medications, are commonly used to treat anxiety and agitation in dementia despite 
contraindications for their use in elderly populations.  It is well documented that 
benzodiazepines with oxidative pathways and longer half-lives are more likely to 
accumulate in elderly individuals, causing prolonged sedation (20).  Older adults are also 
highly susceptible to adverse effects due to age-related increases in the brain’s 
benzodiazepine receptors (20).  As a result, elderly patients are at an increased risk of 
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memory loss, disinhibition, impaired psychomotor ability, and subsequently recurrent 
falls and hip fracture, and motor vehicle accidents (20-22).  Other medications including 
antidepressants and anticonvulsants are associated with blurred vision and dizziness upon 
standing, leading to increased risk of falls and hip fracture (23, 24).  These risks are even 
more pronounced among dementia patients where simultaneous use of multiple 
medications increases the likelihood of adverse drug reactions. 
Despite the risks associated with psychotropic medication use in dementia 
patients, many physicians still advocate for their use.  Pharmacologic management of 
difficult behaviors helps reduce the negative impact of behavioral symptoms on family 
caregivers and helps delay the need for institutionalization (25-27).  Additionally, non-
pharmacologic interventions are not reimbursable and are generally difficult to 
implement in practice—families caring for a demented relative often appeal for 
pharmacotherapy after unsuccessful attempts to manage otherwise (28-30).  
Unfortunately for patients, the risks associated with psychotropic medication may not be 
balanced by the benefit as many of these medications show only minimal to modest 
efficacy (31). 
The practice of prescribing psychotropic medication for the management of mood 
and behavioral dementia symptoms has evolved out of necessity—there are currently no 
approved safe, pharmacologic options available.  As a safeguard against many of the 
risks, federal guidelines regulating psychotropic medication in long-term care facilities 
have been established (32).  Potentially modifiable risk factors for medication have also 
been identified in a rich body of literature examining determinants of psychotropic 
medication use among institutionalized elderly with dementia (33-41).  Despite the 
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progress in our understanding of the issues surrounding psychotropic medication use 
among the elderly with dementia, considerable knowledge gaps remain concerning the 
patterns of use among demented adults living in the community.  First, it is largely 
unknown whether caregiver attributes including perceptions of caregiving influence the 
risk of psychotropic medication use by the care recipient. The role of care recipient pain 
has also not been evaluated.  Second, in spite of our knowledge regarding the increased 
risk of adverse events associated with psychotropic drug use in individuals with 
dementia, little is known about how these medications are used over time as the disease 
progresses and the risk of an adverse event increases.  Finally, there are important health 
disparities in the incidence of dementia and the use of approved anti-dementia 
medications, with little known about the patterns of psychotropic medication use in 
minority, community-dwelling dementia patients.   
Given the current lack of FDA approved medications for the treatment of non-
cognitive dementia symptoms and serious risks associated with the use of psychotropics, 
the goal of research in this area should focus on gaining a more comprehensive 
understanding of the predictors of psychotropic medication use in order to identify 
potentially modifiable targets for non-pharmaceutical intervention.  The studies contained 
within the following dissertation address this goal by utilizing a broad range of care 
recipient and caregiver characteristics as cross-sectional and longitudinal predictors of 
psychotropic medication both between and within racially and ethnically diverse 
populations of community-dwelling dementia patients and their informal caregivers.       
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1.1 Caregiver Perception of Caregiving and Care Recipient Pain as Predictors of 
Psychotropic Medication Use in Community-Dwelling Dementia Patients 
In 2002, 58.9% of the estimated 3.4 million Medicare beneficiaries who were 
diagnosed with Alzheimer’s disease or related dementias resided in the community (42).  
The use of psychotropic medication in this population is quite prevalent with estimates of 
the most dangerous psychotropic, antipsychotics, ranging from 14% to 27% (30, 42).  
Existing investigations into the predictors of psychotropic drug use in community-
dwelling dementia patients have focused on patient characteristics such as age, cognitive 
impairment, and behavior disturbances (43-46), and have neglected the subjective 
caregiver experience.  Informal caregivers, however, are key agents in the plan of care for 
patients with chronic illness such as dementia.  Physicians rely on input from caregivers 
when assessing dementia patients and prescribing treatments (47).  The lack of caregiver 
perceptions in the current studies of psychotropic medication use in community-dwelling 
dementia patients make it difficult to ascertain the extent to which subjective caregiver 
experience influences care recipient medication use.   
Another drawback of the current literature surrounds the limited availability of 
data on care recipient pain.  Pain perception and autonomic responses to pain are altered 
in dementia, and demented individuals are often unable to verbally express pain (48).  As 
a result, it is frequently under-diagnosed and inadequately treated, resulting in pain-
related behavior that can be misinterpreted as a behavioral manifestation of 
neurodegeneration (49).  For example, it has been shown that Alzheimer’s patients with 
arthritis are more likely to receive a benzodiazepine or neuroleptic versus an analgesic 
medication (50).  Similar investigations have found associations between joint pain or the 
  
7 
 
presence of a painful condition and psychotropic medication use (51, 52); however, the 
reliance on self-reported pain measures and institutionalized dementia patients makes it 
difficult to glean whether community-dwelling older adults with dementia have a similar 
experience. 
Using data from the Resources for Enhancing Alzheimer’s Caregiver Health 
(REACH) II randomized trial, Chapter 2 examines predictors of psychotropic medication 
use, going beyond traditional behavioral risk factors and including caregiver perceptions 
of caregiving and care recipient pain in order to obtain a comprehensive understanding of 
the patterns of psychotropic medication use in community-dwelling elderly with 
dementia. 
1.2 Longitudinal Predictors of Psychotropic Medication Use in Community-
Dwelling Dementia Patients 
The heightened concern regarding the use of psychotropic medications in the 
elderly is primarily due to aging-related alterations in physiology and drug metabolism 
which increase the risk of adverse drug reactions and toxicity.  Aging individuals 
experience changes in the receptors that mediate drug efficacy as well as other reactions 
associated with side effects (53).  As a result, elderly users of psychotropic medications 
are at an increased risk of adverse drug events.  Additionally, changes in body 
composition that occur with age alter the distribution, metabolism, and elimination of 
medication, leading to an increased risk of toxicity (53).  These risks are especially 
pronounced in the elderly with chronic conditions such as dementia, as disease pathology 
can exacerbate the effects of normal aging. 
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Understanding the predictors of psychotropic medication is an imperative first 
step in developing interventions aimed at minimizing their use; however, the limited 
number of studies investigating predictors of psychotropic medication among 
community-dwelling elderly with dementia  in the United States were cross-sectional and 
have demonstrated conflicting results (43, 45, 46).  Findings from cross-sectional studies 
with a broader focus on older adults living in the community were also inconclusive (34, 
44, 54).  One possible explanation for the diversity of findings may be that predictors of 
medication change over the course of disease, and thus vary over time.  Using eighteen 
months of follow-up data from the REACH I randomized trial, Chapter 3 examines the 
longitudinal association between caregiver perceptions of caregiving, dementia patient 
symptoms, and the risk of care recipient psychotropic medication to determine whether 
the risk of medication changes over time as health declines and the risk of adverse drug 
events increases. 
1.3 Racial and Ethnic Variation in the Use of Psychotropic Medication for the 
Treatment of Dementia 
In the United States, racial/ethnic minorities bear a disproportionate burden of 
disability and disease (55).  Although disparities in some health outcomes such as 
mortality dissipate in old age (56), multiple studies have reported a higher prevalence of 
dementia among minorities compared to Whites/Caucasians (2, 57, 58).  Racial/ethnic 
differences in health care utilization, particularly the use of prescription drugs, have also 
been observed (59).  For example, a study of Medicare beneficiaries with chronic illness 
found that White/Caucasian patients were more likely to use prescription medication than 
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Black/African Americans and Hispanic/Latinos with the same illness and insurance 
coverage (60).   
The decreased use of prescription drugs by racial/ethnic minorities also extends to 
community-dwelling individuals with dementia.  Several studies of non-institutionalized 
dementia patients have found that non-Hispanic Whites are more likely to receive FDA 
approved anti-dementia medication compared to minority dementia patients (61-63).  In 
contrast, few studies of psychotropic medication use among elderly people living in the 
community exist and, only a small portion focuses exclusively on people with dementia. 
Among investigations that do focus on community-dwelling dementia patients, a 
comprehensive evaluation of potential racial/ethnic disparities is not possible due to 
either the absence of race/ethnicity data in the analysis (45, 46) or the dichotomization of 
race into White and non-White categories (White versus Black, White versus Other) (43, 
44).  Surprisingly, none of the published literature focusing on community-dwelling 
dementia patients examines the patterns of psychotropic medication use among 
community-dwelling Hispanics/Latinos with dementia.  This represents an important 
knowledge gap as a disproportionate share of Hispanic/Latino dementia patients reside in 
the community and are cared for by relatives (64, 65).   
Using baseline data from the REACH II randomized trial in Chapter 4, we 
investigated whether there were racial/ethnic disparities in the use of psychotropic 
medication for the treatment of dementia among a racially and geographically diverse 
group of community-dwelling dementia patients.  We then attempted to use a broad set of 
caregiver and care recipient characteristics to explain the observed disparities.  Finally, 
we examined caregiver and care recipient characteristics as predictors of psychotropic 
  
10 
 
medication within each racial/ethnic group to provide information on the patterns of use 
in understudied minority groups. 
1.4 The Resources for Enhancing Alzheimer’s Caregiver Health Trials 
The analyses presented in this dissertation use data from the Resources for 
Enhancing Alzheimer’s Caregiver Health research programs.  These programs were 
established in 1995 by the National Institute on Aging and the National Institute on 
Nursing Research to develop and test interventions aimed at improving the quality of life 
of dementia caregivers from diverse racial/ethnic groups (66).  The REACH program 
took place in two phases: an initial phase (REACH I) that developed and tested multiple 
theory-driven caregiving interventions, and a second phase (REACH II) that evaluated a 
single, refined, multi-component intervention.  Enrollment for REACH I began in 1996 at 
six sites across the country including Boston, Birmingham, Memphis, Miami, Palo Alto, 
and Philadelphia.  Participants enrolled at each site were assigned to either an active 6-
month intervention or control and were followed for 18 months.  Because the purpose of 
REACH I was to test the effectiveness of multiple intervention approaches aimed at 
improving various dimensions of caregiver quality of life, different interventions were 
implemented at each study site including: individual information and support strategy; 
group support and family systems therapy; psychoeducational and skill-based training 
approaches; home-based environmental interventions; and enhanced technology support 
systems (67).  Consequently, REACH I yielded information about the feasibility and 
outcomes of multiple intervention approaches instead of providing definitive information 
on the efficacy of one specific strategy for enhancing caregiver quality of life (66).   
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Several important observations were made in REACH I.  First, caregivers 
experienced difficulties in several areas of caregiving at varying levels of intensity.  
Second, active interventions were superior to control conditions in reducing caregiver 
burden.  Finally, active interventions that emphasized caregiver engagement were the 
most successful at reducing caregiver depression (68).  These findings identified the most 
promising methods for improving caregiver quality of life and helped investigators 
design the multi-component intervention used in REACH II. 
Recruitment for REACH II began in June 2002 at five sites across the country 
including Birmingham, Memphis, Miami, Palo Alto, and Philadelphia.  The goal of this 
phase of the research program was to test an intervention developed to improve caregiver 
depression, burden, self-care, social support, and care recipient problem behaviors.  
Unlike REACH I, the same intervention was used at each study site and consisted of 
several components including provision of information, didactic instruction, role playing, 
problem solving, skills training, stress management techniques, and telephone support 
groups (69).  The intervention lasted for six months and was tailored to meet the specific 
needs of each caregiver.  Final analyses revealed that the multi-component intervention 
significantly improved caregiver quality of life as measured by depression, burden, self-
care, social support, and care recipient problem behaviors for White and Hispanic 
caregivers.  Statistically significant improvements were only observed for Black, spousal 
care caregivers (69). 
Although the goals of this dissertation include examining the predictors of 
psychotropic medication use in community-dwelling elderly and do not include 
evaluating a caregiver intervention, we chose to use the REACH data for several reasons.  
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First, both REACH interventions include a large number a large sample that, from a 
caregiver perspective, has been well-described.  REACH also contains information about 
community-based psychotropic medication use.  Finally, the REACH trials included a 
large number of minority caregivers and care recipients.  Together, these data sets 
provide an ideal opportunity to test hypotheses about predictors of psychotropic 
medication use in community-dwelling dementia patients and to evaluate racial/ethnic 
disparities in psychotropic medication use. 
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Table 1.1 Comparison of REACH I and REACH II Interventions 
 REACH I REACH II 
Sites Treatment Control Treatment Control 
Boston Telephone-linked 
computer system 
designed with access 
to voicemail caregiver 
bulletin board, ask an 
expert option, and 
care recipient 
behavioral distraction 
Written information 
about dementia 
caregiving and 
referral services 
Did not participate in REACH II 
Birmingham Skills training that 
stressed problem-
solving  
Telephone support 
that included empathy 
and active listening, 
and written 
information 
Education about 
depression, burden, 
self-care, social 
support, and problem 
behaviors 
 
Teaching and 
practicing strategies 
for mood management, 
stress management, 
engaging in healthy 
behaviors, accessing 
social services, 
communicating with 
health care providers 
and family members, 
and managing care 
recipient problem 
behaviors 
 
Telephone system to 
connect caregivers 
with information 
Education packet and 
2 brief “check-in” 
calls 
 
Dementia caregiving 
workshop at the end 
of intervention 
Memphis Written information 
plus skills training or 
written information, 
skills training, plus 
behavior modification 
strategies 
Written information 
about dementia 
caregiving and 
referral services 
Miami In-home family 
systems therapy or in-
home family systems 
therapy plus computer 
telephone integration 
system that provides 
special access to 
therapist  
Telephone support 
that included empathy 
and active listening, 
and written 
information 
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Table 1.1 Continued 
 REACH I REACH II 
Sites Treatment Control Treatment Control 
Palo Alto Coping with 
caregiving class that 
taught coping and 
mood management 
skills or enhanced 
support group 
Telephone support 
that included empathy 
and active listening, 
and written 
information 
(Copied from above) 
 
Education on 
depression, burden, 
self-care, social 
support, and problem 
behaviors 
 
Teaching and 
practicing strategies 
for mood management, 
stress management, 
engaging in healthy 
behaviors, accessing 
social services, 
communicating with 
health care providers 
and family members, 
and managing care 
recipient problem 
behaviors 
 
Telephone system to 
connect caregivers 
with information 
 
 
Education packet and 
2 brief “check-in” 
calls 
 
Dementia caregiving 
workshop at the end 
of intervention 
Philadelphia Environmental skills 
building program that 
provided caregivers 
with skills and 
technical support to 
modify the home  
Written information 
about dementia 
caregiving and 
referral services 
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Chapter 2  
 
Caregiver and Care Recipient Characteristics as Predictors of Psychotropic 
Medication Use in Community-Dwelling Dementia Patients 
 
2.1 Background 
The current practice of prescribing psychotropic medications to Alzheimer’s and 
dementia patients for the management of behavior disturbances has generated substantial 
debate as evidence of serious side effects has emerged (1).  In April 2005 the Federal 
Food and Drug Administration (FDA) mandated that a black box warning surrounding 
the increased risk of stroke and death be placed on all atypical antipsychotics.  This 
mandate came after a meta-analysis of 17 well-designed, clinical trials among elderly 
dementia patients revealed that atypical antipsychotics were associated with significantly 
greater mortality risk versus placebo (2).  The FDA warning was extended to typical 
antipsychotics in 2008. 
Other psychotropic medications commonly prescribed to dementia patients also 
carry substantial risks.  For example, benzodiazepines are commonly used to treat anxiety 
and agitation in dementia despite contraindications for their use in elderly populations 
due to increased risk of memory loss, increased sedation, disinhibition, impaired 
psychomotor ability, and subsequently recurrent falls and hip fractures (3).   Tricyclic 
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antidepressants and selective serotonin reuptake inhibitors increase the risk of falls and 
hip fracture in the elderly (4). 
Despite the risks associated with psychotropic medication use in dementia 
patients, many physicians still advocate for their use.  Pharmacologic management of 
difficult behaviors reduces the negative impact of behavior symptoms on family 
caregivers and helps delay the need for institutionalization (5, 6).  Additionally, non-
pharmacologic interventions are not reimbursable and may be difficult for families to 
implement at home—families caring for a demented relative often appeal for 
pharmacotherapy after unsuccessful attempts to manage otherwise (7).  In order to make 
informed decisions regarding appropriate pharmacotherapy for dementia patients, it is 
important to understand the determinants of psychotropic medication use.   
   Many investigations into the predictors of psychotropic medication use have 
focused on dementia patients in formal care settings and cannot be generalized to patients 
living in the community (8-11).  One notable exception is a recent study examining 
determinants of atypical antipsychotic use among community-dwelling elderly currently 
using antipsychotic medication.  Findings indicated that perceived poor mental health 
increased the risk of antipsychotic use (12); however, it is unknown whether these 
associations are influenced by the perceptions of the caregiver or exist within the 
subpopulation of community-dwelling, demented, elderly.  Typically, within this group 
of patients, medication is administered by informal caregivers; however, input from 
caregivers is not usually considered in studies of medication use among community-
dwelling dementia patients.  Such information was omitted in a recent report linking 
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aggressive behaviors to anxiolytic and antipsychotic use in community-dwelling patients 
with newly diagnosed dementia (13).   
   The role of pain in psychotropic medication use among community-dwelling 
elderly with dementia is also overlooked.  Pain perception and autonomic responses to 
pain are altered in dementia (14).  Additionally, individuals with dementia are often 
unable to verbally express pain, and as a result, it cannot be adequately managed (15).  
Unaddressed pain manifests in ways that are strikingly similar to the symptoms of 
dementia (16).  In fact, it is difficult to differentiate between behavioral and 
psychological symptoms of dementia and the behaviors associated with severe physical 
pain (1).  Luijendijk et al. (2008) found that joint pain was associated with an increased 
risk of new-onset, chronic, benzodiazepine use in a cohort of non-demented persons aged 
57 years or older (17).  Another study found a positive association between the presence 
of a pain-related diagnosis and the use of psychotropic medication in elderly dementia 
patients (18).  Both of these investigations examined people living in formal care 
facilities, making it difficult to determine the unique experience of dementia patients 
living in the community. 
Given the gaps in the literature regarding the determinants of psychotropic 
medication use among dementia patients living outside of skilled nursing facilities, the 
goal of this study was to identify patient and caregiver characteristics that predict use of 
anxiolytics, antipsychotics, and antidepressants in the care recipient.  Using data collected 
from the baseline assessment of the Resources for Enhancing Alzheimer’s Caregiver 
Health II (REACH II) randomized clinical trial, we hypothesized that: 
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(1) Caregiving burden and patient attributes, particularly behavior 
disturbances and physical pain, would be associated with increases in 
psychotropic medication. 
(2) Caregiver attributes such as vigilance, and perceived positive aspects of 
caregiving would be associated with decreases in psychotropic 
medication. 
2.2 Methods 
Sample 
The data for this study were drawn from the baseline assessment of REACH II 
(ClinicalTrials.gov Identifier NCT00177489).  Recruitment procedures, eligibility 
criteria, and psychometric properties of all measures and intervention outcomes are 
described elsewhere (19).  The primary goal of the REACH II trial was to evaluate a 
multi-component, psychosocial intervention aimed at improving the quality of life of 
Alzheimer’s caregivers.  In total, 642 community-dwelling Alzheimer’s care recipients 
and their caregivers were recruited throughout 2001-2004 from five sites across the 
country (Birmingham, AL; Memphis, TN; Miami, FL; Palo Alto, CA; and Philadelphia, 
PA).  Only participants with full baseline information on study predictors and outcomes 
were included in the current analyses (N=598). 
Outcome Measures 
 This study focused on care recipient use of anxiolytic, antipsychotic, and 
antidepressant medications as the primary outcome measures.  Information on 
medications was collected using the “brown bag” method of medication collection (20).  
Accordingly, caregivers were asked to bring all currently administered medications to the 
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in-person interview.  Medication names were recorded by study personnel and assigned a 
therapeutic classification code (21).  Although more detailed information on drug dosages 
and duration of use would have been desirable, these were not collected as the analysis of 
prescription medication was not a primary objective of the REACH II trial. 
Predictors 
This study considered several caregiver characteristics and care recipient 
dementia symptoms as predictors of psychotropic medication use in the care recipient.  
Primary variables of interest included care recipient baseline cognitive status as measured 
by the Mini-Mental State Examination (total scores range from 0 to 30, with higher 
scores indicating better cognitive functioning; scores less than or equal to 24 indicate 
cognitive impairment) (22); care recipient functional impairment status as measured by 
the ability to independently perform basic and instrumental activities of daily living 
(ADLs and IADLs respectively; possible scores ranged from 0 to 14 with higher scores 
indicating more functional impairment) (23); the extent to which a caregiver was 
bothered by assisting with functional limitations (daily care bother; final scores ranged 
from 0=not at all to 4=extremely) (24); the presence of problem behaviors as measured 
by the Revised Memory and Behavior Problem Checklist (RMBPC) (scores range from 
0-24 with higher scores indicating more problematic behaviors) (25); the extent to which 
caregivers were bothered by the problem behaviors (final scores ranged from 0=not at all 
to 4=extremely) (24); and the amount of confidence caregivers had in handling the 
problem behaviors (24).  No direct measure of pain was collected in REACH II; however, 
information on care recipient analgesic medication use was available.  Previous research 
supports the use of analgesic medication as a proxy for pain (26); therefore, care recipient 
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use of a narcotic or COX-2 inhibitor was utilized as a dichotomous surrogate for pain.  
Non-steroidal anti-inflammatory agents (NSAIDs) were not considered here as they have 
historically been used to manage low levels of chronic pain that cannot necessarily be 
eliminated (27).  Additionally, NSAIDs such as aspirin are often used to decrease platelet 
aggregation and prevent blood clots (28).  An overwhelming majority of the NSAID use 
in this study was aspirin (74.76%).  Therefore, we focused on the presence of a narcotic 
or COX-2 inhibitor as surrogate for pain. 
 Other variables of interest focused exclusively on the caregiver and include 
income adequacy, as measured by perceived difficulty with paying for basics (scores 
range from 1=not difficult at all to 4=very difficult); self reported health (both current 
and current versus six months previous; scores range from 0-5 with higher scores 
indicating poorer health) (29); depression, as measured by the 10-item version of the 
Center for Epidemiological Studies-Depression Scale (CES-D), (scores range from 0 to 
30, with higher scores indicating greater depressive symptomatology; scores of 16 or 
greater may indicate clinically significant depression) (30); overall caregiving burden as 
measured by an abbreviated, 12-item version of the Zarit Caregiver Burden Inventory 
(total scores range from 0 to 48, with higher scores indicating greater burden) (31, 32); 
caregiving mastery, assessed by eight items developed by REACH investigators (33) 
(total scores ranged from 0 to 16 with lower scores indicating greater mastery); vigilance, 
as measured by the hours per day a caregiver reported needing to be “on duty”  to care for 
the care recipient (33); positive aspects of caregiving, as measured by the nine-item 
Positive Aspects of Caregiving Scale (total scores ranged from 0 to 36, with higher scores 
indicating more positive appraisals of the caregiving situation) (34); spiritual and 
 30 
 
religious coping as assessed by nine questions asking caregivers to rate the extent to 
which religious and spiritual beliefs affect their caregiving (total scores ranged from 0 to 
18 with higher scores indicating greater spiritual and religious coping) (35); and finally, 
dementia knowledge as measured by the caregiver’s general knowledge of memory loss, 
dementia, and end of life legal issues (total scores range from 0 to 4, with higher scores 
indicating greater knowledge of dementia). 
 Several dimensions of social network were also examined in this investigation 
including network size, support satisfaction, and negative social interactions by 
modifying questions from several pervious measures of social interaction and support 
(36-38).  Social network size was assessed with two questions regarding the number of 
people who can be counted on to provide help.  Total scores range from 0 to 10 with 
higher scores indicating larger social networks. Caregiver satisfaction with the help 
received from social contacts was assessed with three questions.  Total scores range from 
0 to 9, with higher scores indicating more satisfaction.  Finally, the presence of negative 
social interactions was assessed with four questions asking caregivers to rate the 
frequency of negative interactions on a four-point scale.  Total scores ranged from 0-12 
with higher scores indicating a greater frequency of negative social interactions.  
Potential Confounders 
This study considered care recipient race (White, Black, Hispanic, 
Unknown/Other), sex (male/female), age at baseline, and caregiver relationship to the 
care recipient (spouse/non-spouse) as potential confounders of the association between 
caregiver and care recipient characteristics and care recipient psychotropic medication 
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use.  Caregiver race was highly correlated with care recipient race and was therefore not 
considered in this investigation. 
Statistical Analysis 
 Descriptive statistics were computed for important demographic variables to 
provide a basic understanding of sample characteristics.  Tetrachoric correlations 
between medications were also examined.  Non-linear mixed models with a logit link 
were used to account for clustering within intervention site while estimating the 
association between caregiver and care recipient characteristics and care recipient 
psychotropic medication use.  The mathematical equation for the regression models used 
is presented in Section 2.5, Supplemental Equations. 
Based on previous observations that predictors of psychotropic medication vary 
across medication type (39), regression analyses for each psychotropic medication 
outcome proceeded in two stages.  First, preliminary models were utilized to examine the 
association between each predictor and the odds of medication use, while controlling for 
confounding variables.  Predictors with a p-value less than or equal to 0.10 were retained 
for use in the next stage of the analysis because it would be otherwise unlikely that a 
covariate would contribute to a multivariable model.  All predictors retained from the 
preliminary analyses were then included in multivariable models that controlled for 
potential confounding variables.  Estimates from the multivariable models were 
considered statistically significant at the 5% level. 
2.3 Results 
 Demographic information for study participants is presented in Table 2.1.  As 
shown in Table 2.2, care recipients displayed an average of 11 problem behaviors in the 
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past week.  These behaviors caused caregivers “a little” to a “moderate” amount of 
bother.  Figures 1.1 and1.2 display the prevalence of psychotropic medication use in the 
study sample.  As shown in Figure 2.1, the prevalence of psychotropic medication use in 
this sample was high, with approximately 59% of participants using at least one 
anxiolytic, antipsychotic, or antidepressant.  Figure 2.2 displays the prevalence of each 
psychotropic medication type.  Over a quarter of care recipients were using an 
antipsychotic or antidepressant.  Approximately 18% of care recipients used an 
anxiolytic.  The correlation between study medications is shown in Table 2.3.  
Anxiolytics were significantly but weakly correlated with antipsychotics and pain 
medications (r=0.11 and r=0.09 respectively).  Antidepressants demonstrated a 
significant, but weak correlation with antipsychotics (r=0.09).  No significant correlations 
were observed between the remaining medications. 
Anxiolytics 
Anxiolytic medications were used by 105 care recipients.  Of these care 
recipients, 20% were also taking an antipsychotic (n=21), 22.86% were taking an 
antidepressant (n=24), and 17.14% were taking all three psychotropic medications 
(n=18).  Bivariate associations between study predictors and psychotropic medications 
are shown in Table 2.4.  More functional impairment and increases in disruptive 
behaviors were significantly associated with an increased use of anxiolytics (α=0.10 for 
preliminary analyses).  Depression, burden, and vigilance were also associated with more 
anxiolytic use.  Larger social networks, greater confidence managing problematic 
behaviors, more financial strain, and greater self-reported health were associated with 
reduced use of anxiolytics. 
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 Fit statistics from the multivariable model indicated that the model fit was 
appropriate (χ2/df=1.03); therefore, model estimates were evaluated and are shown in 
Table 2.5.  Less care recipient functional status, more problematic behaviors, and pain 
were associated with increased odds of medication use; however, the estimates were not 
statistically significant (OR=1.07, p=0.11; OR=1.03, p=0.37; OR=1.74, p=0.07 
respectively).  Caregiver vigilance was associated with greater anxiolytic use (OR=1.06, 
p<0.01) whereas increased confidence managing problematic behaviors was protective 
(OR=0.76, p=0.04). 
Antipsychotics 
 One hundred and sixty-one care recipients were using antipsychotic medications.  
Of these care recipients, 14.43%  had concomitant anxiolytic medication use (n=21), 
32.92% had concomitant antidepressant use (n=53), and 11.18% used all three 
psychotropic medications (n=18) The bivariate associations presented for antipsychotic 
medications in Table 2.4 show that care recipient cognitive and functional impairment 
were associated with increased use of antipsychotics.  Care recipient characteristics 
including poor physical health and increased hours of vigilance were also associated with 
increased antipsychotic use.  As with anxiolytics, model fit statistics indicated that the 
multivariable model was an appropriate fit (χ2/df=1.03).  Results from the model are 
presented in Table 2.5.  Compared to White care recipients, Black and Hispanic care 
recipients were significantly less likely to take antipsychotic medication (OR=0.60, 
p=0.03; OR=0.47, p<0.01 respectively).  Greater care recipient functional impairment 
and pain was associated with increased use of antipsychotics (OR=1.08, p=0.05; 
OR=1.70, p=0.05).  Increases in caregiver vigilance were also associated with 
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antipsychotic use; however, the estimate was not statistically significant (OR=1.02, 
p=0.28). 
Antidepressants 
A total of 221 care recipients were using an antidepressant medication.  Of those 
care recipients, 10.86% were also taking an anxiolytic (n=24), 53 were also taking an 
antipsychotic (23.98%) and 18 were taking all three medications (8.14%).  As shown in 
Table 2.4, higher care recipient cognitive status, greater caregiver financial strain, and 
more dementia knowledge were associated with greater use of antidepressants.  The use 
of spiritual and religious coping as well as perceiving positive aspects of caregiving were 
associated with reduced use of antidepressants. 
Model fit statistics from the multivariable model indicated that the model was an 
appropriate fit (χ2/df=1.01).  Results from the multivariable model are presented in Table 
2.5.  Younger care recipient age and better cognitive status were associated with more 
antidepressant use (OR=0.97, p<0.01.; OR=1.04, p<0.01 respectively).  Higher levels of 
dementia knowledge were also associated with greater use of antidepressants (OR=1.18, 
p=0.02). 
2.4 Discussion 
 This study utilized care recipient and caregiver attributes as predictors of 
anxiolytic, antipsychotic, and antidepressant medication use in community-dwelling 
dementia patients.  Our findings revealed that psychotropic medication is influenced both 
by the needs of the care recipient and the subjective experience of the informal dementia 
caregiver.   
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In accordance with study hypotheses, more problematic behaviors were 
significantly associated with increased odds of anxiolytic medication, however; this 
association was only observed in bivariate analyses and did not remain when caregiver 
attributes were included in multivariable analyses.  This is in contrast to Kunik et al. who 
found an increased risk of anxiolytic and antipsychotic use associated with aggressive 
behaviors among community-dwelling elderly with dementia (13).  The lack of an 
observable association between problematic behaviors and psychotropic medication in 
this study may be partially explained by the global nature of the RMBPC.  Its focus on a 
wide range of problematic behaviors experienced in dementia may not be sensitive 
enough to capture specific aggressive behaviors that would most likely be associated with 
psychotropic medication therapy.   
 Another potential explanation for the discrepant findings may be the inclusion of 
caregiver characteristics in the present study.  Informal caregivers are key agents in the 
plan of care for patients with chronic illness such as dementia.  Physicians rely on input 
from caregivers when assessing dementia patients and prescribing treatments.  Failure to 
include caregiver assessment may exaggerate the relation between dementia symptoms 
and pharmacologic treatment found in the Kunik study.   
 We also found a positive association between pain, as measured by the use of a 
prescription narcotic or COX-2 inhibitor, and the use of an anxiolytic or antipsychotic 
medication, although the estimated effect was not statistically significant for anxiolytics.  
This result is consistent with a recently published study that identified joint pain as a risk 
factor for chronic benzodiazepine use in a cohort of non-demented, community-dwelling 
elderly (17) and also work that found a positive association between having a pain-related 
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diagnosis and the use of psychotropic medication in elderly dementia patients (18).  Our 
results enrich these findings by generalizing the type of pain under investigation, 
including multiple medication outcomes, and demonstrating that the association between 
pain and anxiolytic use holds among demented adults living in the community.  
 This study is the first to comprehensively evaluate caregiver attributes as risk 
factors for multiple types of psychotropic medication use in community-dwelling 
dementia patients.  In accordance with study hypotheses, we found that caregiver 
confidence and positive aspects of caregiving were associated with reductions in care 
recipient anxiolytic and antipsychotic use.  This is consistent with investigations of other 
dementia care recipient health outcomes such as institutionalization.  A 2009 review by 
Gaugler et al. found overwhelming evidence that caregiver attributes such as the feeling 
of losing one’s self to caregiving was positively associated with institutionalization (40).  
There is also support for an association between a caregiver’s sense of entrapment and 
dementia patient maltreatment (41).  The consistent association between caregiver 
attributes and various dementia patient health outcomes suggests that an underlying 
causal mechanism may be acting.  If so, the risk factors for psychotropic medication use 
identified here may also be useful for predicting other dementia patient health outcomes.  
Epidemiologic studies of community-dwelling dementia patients should include measures 
of caregiver characteristics to better elucidate the role that informal dementia caregivers 
play in care recipient health. 
 The results of this study should be considered in light of the following limitations.  
First, this investigation was cross-sectional and did not contain dose information and 
therefore cannot be used to determine the influence of caregiver and care recipient 
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characteristics on the intensity or duration of psychotropic medication use.  Future studies 
with longitudinal dosing data should be utilized to examine risk factors for chronic 
psychotropic medication use in community-dwelling, demented populations.  Second, 
care recipient pain was determined by the use of pain management medication.  Our 
study found that individuals being treated with either a narcotic or COX-2 inhibitor were 
at an increased risk of anxiolytic or antipsychotic use.  Previous research has found an 
association between narcotic medication use and delirium (42).  Therefore, it is possible 
that our findings reflect a practice of polypharmacy where drug-induced delirium is 
addressed with psychotropic medication.  Addressing this issue with cross-sectional data 
is difficult; however, the correlation between pain medication, anxiolytics, and 
antipsychotics in this study was small, suggesting that influence of polypharmacy in our 
study was minimal.  A plausible alternative explanation of these results is that pain was 
not adequately managed, even among those receiving treatment.  This interpretation is 
supported by research indicating that pain among older adults with severe cognitive 
impairment is often under-diagnosed and undertreated (43).  Future studies should 
incorporate pain data either in the form of observational assessment or an inventory of 
painful co-morbid conditions to verify the results of this study.  Third, REACH II was a 
randomized study.  Therefore, our results are not necessarily generalizable to the 
population of community-dwelling dementia patients and their caregivers.  
Finally, the data for REACH II were collected before the FDA issued the first 
black box warning on the increased risk of death associated with antipsychotics in the 
elderly.  These warnings may be influencing current treatment patterns by shifting 
antipsychotic prescriptions to other pharmacologic or nonpharmacologic options.  A 2010 
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study by Dorsey et al. found a substantial decrease in the use of atypical antipsychotics 
among elderly patients with dementia following the FDA advisory.  Despite the decrease, 
however, atypicals remained the most popular class of therapeutics among dementia 
patients, ranking second only to acetylcholinesterase inhibitors in each year of the study 
(44).  Therefore, understanding the predictors of antipsychotic drug use in community-
dwelling dementia patients is still a timely and important area of gerontological research. 
Despite the discussed limitations, this study establishes a benchmark for 
evaluating both caregiver and care recipient characteristics as risk factors for 
psychotropic medication use among dementia patients living in the community.  This is 
the first study to identify caregiver confidence as a protective factor for dementia patient 
psychotropic medication use, and as a result, emphasizes the importance of a 
comprehensive approach to dementia care.  Addressing the needs of informal caregivers 
is essential for maintaining the health and well being of the care recipient.  More work is 
needed to assess the extent to which interventions aimed at improving caregiver 
confidence and appraisal reduces psychotropic medication use in dementia patients.  
Furthermore, our results highlight the need for better pain management strategies 
specifically among community-dwelling elderly with dementia. 
 In conclusion, this study suggests that caregiver and care recipient characteristics 
are important predictors of psychotropic medication use in community-dwelling dementia 
patients.  Our work provides support for the concept of caregivers as a secondary victim 
of dementia by demonstrating the negative influence of long-term caregiving on 
caregiver mental health and subsequently the health of care recipients.  Providing support 
services to family caregivers may be a reasonable strategy for decreasing psychotropic 
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drug use among community-dwelling dementia patients while also improving caregiver 
quality of life.  
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2.5 Supplemental Equations 
The following equation is a mathematical representation of the non-linear mixed 
models used to assess study hypotheses (45). 
݈݋݃݅ݐ ൫ߨ௜௝൯ ൌ  ߙ௝ ൅ ߚݔ௜௝+ eij 
ߙ௝ ൌ ߙ ൅ ݑ௝ 
Where ߨ௜௝ is the probability of medication for the ith care recipient at the jth site. 
ߙ௝ (j=1,…,5) is a linear combination of the grand mean (α) and a deviation (uj), 
where uj is assumed to be normally distributed ~ܰሺ0, ߪ௨ଶሻ and independent of the 
care recipient level random errors (eij).  
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Table 2.1 Caregiver and Care Recipient Demographic Information 
Demographics Caregiver Care recipient 
  Age, years   
    Mean (SD) 59.55 (13.09) 79.06 (9.26) 
  Sex, n (%)   
    Female 494 (82.61) 353 (59.03) 
    Male 104 (17.39) 245 (40.97) 
  Race, n (%)   
    White 214 (35.79) 214 (35.79) 
    Black 192 (32.11) 186 (31.10) 
    Hispanic 192 (32.11) 183 (30.60) 
    Other/Unknown 0 (0.00) 15 (2.51) 
  Relationship to care recipient, n (%)   
    Spouse 254 (42.47)  
    Non-spouse 344 (57.53)  
  Years caring for care  
  recipient 
  
    Mean (SD) 4.93 (7.32) - 
SD=Standard deviation  
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Table 2.2 Descriptive Statistics for Study Predictors and Outcomes* 
Study predictors and outcomes Mean (SD) Range† 
Care recipient attributes   
Cognitive status 12.42 (7.33) 0-30 
  Functional impairment 10.06 (3.11) 0-14 
  Number of problem behaviors endorsed 10.69 (3.98) 0-24 
  Pain, n (%) 75 (12.54) - 
Caregiver attributes   
  Self-reported health   
    Overall current health 2.11 (1.07) 0-4 
    Overall current health compared to 6 months  
    previous 
2.12 (0.85) 0-4 
  Caregiver depression 10.02 (6.51) 0-60 
  Caregiver burden 17.32 (8.88) 0-48 
  Daily care bother 0.77 (0.79) 0-4 
  Problem behavior bother 1.47 (0.90) 0-4 
  Problem behavior confidence 2.04 (0.93) 0-4 
  Mastery 5.94 (2.88) 0-6 
  Vigilance 19.30 (6.73) 0-24 
  Positive aspects of caregiving 25.45 (8.97) 0-36 
  Spiritual and religious coping 14.74 (3.54) 0-18 
  Social Network   
    Social network size 6.38 (2.31) 0-10 
    Social support satisfaction 4.95 (2.82) 0-9 
    Negative social interaction 2.84 (2.75) 0-12 
  Income adequacy 1.62 (1.03) 0-3 
  Dementia knowledge 2.12 (1.32) 0-4 
Outcomes, n (%)    
  Anxiolytics 105 (17.56) - 
  Antipsychotics 161 (26.92) - 
  Antidepressants 221 (36.96) - 
*All values are presented as means and standard deviations, except where  
 otherwise noted 
†Range of the measurement instrument 
SD=Standard deviation  
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Table 2.3 Correlation Between Study Medications 
 
Variable 
 
1 
 
2 
 
3 
 
4 
1. Anxiolytic -    
2. Antipsychotic 0.11* -   
3. Antidepressant 
4. Pain (Narcotic or 
COX-2 inhibitor) 
0.03 
0.09* 
0.09*
0.08 
- 
0.03 
 
- 
*p≤0.05 
  
 44 
 
Table 2.4 Bivariate Associations Between Study Predictors and Psychotropic 
Medications* 
Variable Anxiolytics Antipsychotics Antidepressants 
 Odds 
ratio 
95% CI Odds 
ratio 
95% CI Odds 
ratio 
95% CI 
Care recipient attributes       
  Cognitive status 1.00 (0.97, 1.03) 0.97† (0.94, 0.99) 1.04† (1.01,  1.06) 
  Functional impairment 1.09† (1.01, 1.18) 1.11† (1.04, 1.19) 1.02 (0.97,  1.09) 
  Problem behavior  
  frequency 1.06† (1.00,1.12) 1.02 (0.97, 1.07) 1.02 (0.98,  1.06) 
  Pain 1.80† (1.02, 3.19) 1.75† (1.03, 2.97) 1.23 (0.75,  2.04) 
Caregiver attributes       
  Self-reported health       
    Overall current health 1.26† (1.03,1.55) 1.16† (0.97, 1.38) 0.99 (0.85,  1.16) 
    Overall current health    
    compared to 6 months   
    previous 1.18 (0.90, 1.53) 1.30† (1.02, 1.64) 0.96 (0.78,  1.17) 
  Caregiver depression 1.05† (1.02, 1.09) 1.02 (0.99, 1.05) 1.00 (0.98,  1.03) 
  Caregiver burden 1.03† (1.00, 1.05) 1.01 (0.99, 1.03) 1.01 (0.99,  1.03) 
  Daily care bother 0.96 (0.73, 1.27) 1.09 (0.86, 1.37) 0.99 (0.80, 1.23) 
  Problem behavior  
   bother 1.20 (0.95, 1.53) 0.94 (0.76, 1.16) 1.07 (0.88, 1.29) 
  Problem behavior  
  confidence 0.68† (0.54, 0.87) 0.97 (0.80, 1.19) 1.03 (0.86,  1.24) 
  Mastery 1.00 (0.93, 1.08) 1.03 (0.97,  1.10) 1.01 (0.95, 1.07) 
  Vigilance 1.07† (1.03, 1.12) 1.03† (1.00, 1.06) 1.01 (0.98, 1.03)
  Positive aspects of  
  caregiving 0.99 (0.97, 1.01) 0.98 (0.96, 1.00) 0.97† (0.96, 0.99) 
  Spiritual and religious  
  coping 1.02 (0.96, 1.08) 1.02 (0.97, 1.08) 0.94† (0.89,  0.98) 
  Social Network       
    Social network size 0.90† (0.82, 0.98) 1.05 (0.96, 1.14) 1.00 (0.93, 1.07) 
    Social support  
    satisfaction 0.96 (0.89,1.04) 1.01 (0.95, 1.09) 0.98 (0.92, 1.04) 
    Negative social  
    interaction 1.01 (0.94, 1.09) 0.98 (0.92, 1.05) 0.94 (0.89, 1.01) 
  Income adequacy 0.81† (0.66, 1.00) 0.88 (0.73, 1.05) 1.16† (0.98, 1.36) 
  Dementia knowledge 0.96 (0.81, 1.13) 0.95 (0.83, 1.10) 1.22† (1.07, 1.40) 
* Estimates from non-linear mixed models controlling for recipient race (White, Black, 
Hispanic, Unknown/Other), sex (male/female), age at baseline, and caregiver relationship 
to the care recipient (spouse/non-spouse) 
†p≤0.10 
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Table 2.5 Multivariable Model Predicting Use of Anxiolytic, Antipsychotic, and 
Antidepressant Medication* 
Variable Anxiolytics Antipsychotics Antidepressants 
 Odds 
ratio 
95% CI Odds 
ratio 
95% CI Odds 
ratio 
95% CI 
Care recipient attributes       
  Race       
   White REF - REF - REF - 
    Black 1.72 (0.99, 3.01) 0.60†   (0.37, 0.95) 1.01  (0.66, 1.56) 
    Hispanic 0.94 (0.51, 1.74) 0.47†   (0.27, 0.81) 0.72  (0.46, 1.13) 
    Other/Unknown 2.12 (0.59, 7.62) 0.72  (0.21, 2.42) 1.05  (0.34, 3.20) 
  Sex       
   Female REF - REF - REF - 
   Male 1.21 (0.69, 2.11) 0.64 (0.39, 1.05) 1.14   (0.73, 1.78) 
  Age at baseline 0.99 (0.97, 1.01) 0.99  (0.97, 1.01) 0.97† (0.96, 0.99) 
  Cognitive status   0.98 (0.95, 1.00) 1.04†    (1.01, 1.06) 
  Functional impairment 1.07 (0.98, 1.15) 1.07† (1.00, 1.15)   
  Problem behavior  
  frequency 1.03 (0.97, 1.09)     
  Pain       
   No REF - REF - REF - 
   Yes 1.74 (0.96, 3.15) 1.70† (1.00, 2.92)   
Caregiver attributes       
  Relationship to care  
  recipient 
      
   Spouse REF - REF - REF - 
   Non-Spouse 0.99 (0.56, 1.77) 0.94 (0.57, 1.55) 1.16 (0.74, 1.84) 
Self-reported health       
    Overall current health 1.08 (0.87, 1.36) 1.08  (0.89, 1.30)   
    Overall current health    
    compared to 6 months   
    previous   1.23 (0.96, 1.57)   
  Caregiver depression 1.02 (0.97, 1.06)     
  Caregiver burden 1.00 (0.97, 1.03)     
  Problem behavior  
  confidence 0.76† (0.59, 0.99)     
  Vigilance 1.06 † (1.01, 1.10) 1.02  (0.98, 1.05)  
  Positive aspects of  
  caregiving     0.99    (0.97, 1.01) 
  Spiritual and religious  
  coping     0.96 (0.91, 1.01) 
  Social Network       
   Social network size 0.94 (0.85, 1.05)     
  Income adequacy 0.94 (0.74, 1.19)   1.04   (0.87, 1.24) 
  Dementia knowledge     1.18†    (1.02, 1.35) 
*Estimates from non-linear mixed models controlling for care recipient race, sex, age at baseline, and 
caregiver relationship to the care recipient 
†p≤0.05 
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Figure 2.1 Overall Prevalence of Psychotropic Medication Use 
 
 
 
Figure 2.2 Prevalence of Psychotropic Medication Use by Medication 
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Chapter 3  
 
A Longitudinal Investigation of Psychotropic Medication Use Among Community-
Dwelling Dementia Patients 
 
3.1 Background 
 Psychotropic medication has a long history of use in dementia.  Although never 
approved for this indication, several medications including anxiolytics, antipsychotics, 
and antidepressants were commonly used “off-label” to manage mood and behavioral 
symptoms of the disease (1).  In April 2005, this practice came under considerable 
scrutiny as the Federal Food and Drug Administration (FDA) mandated that a warning 
surrounding the increased risk of stroke and death be placed on all atypical antipsychotics 
(2).  The warning was extended to typical antipsychotics in 2008. 
The heightened concern regarding the use of psychotropic medications in the 
elderly is primarily due to aging-related alterations in physiology and drug metabolism 
which increase the risk of adverse drug reactions and toxicity (3).  Aging individuals 
experience changes in the receptors that mediate drug efficacy as well as other reactions 
associated with side effects.  Additionally, changes in body composition that occur with 
age alter the distribution, metabolism, and elimination of these medications (3).  As a 
result, elderly users of psychotropic medications are at an increased risk of adverse drug 
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reactions and drug toxicity.  These risks are especially pronounced in the elderly with 
chronic conditions, as disease pathology can exacerbate the effects of normal aging. 
 Despite the risks, use of psychotropic medications is very common among elderly 
populations (4, 5).  In the United States, research surrounding the use of psychotropic 
medication in the elderly is largely focused on residents of long-term care facilities (6-9). 
Studies of medication use among community-dwelling elderly are rare, and published 
work examining medication use among community-dwelling elderly with dementia are 
even fewer in number (4, 10-12).  This is a particularly important area of research given 
that a majority of dementia patients remain in the community and are cared for by 
relatives (13).    
The few studies in the US that have investigated predictors of psychotropic 
medication use among community-dwelling elderly with dementia have demonstrated 
conflicting results.  An early work by Semla et al. found that lower cognitive function 
was associated with the use of antipsychotic agents and benzodiazepines.  Mood changes 
with no precipitating cause and hallucinations were significantly associated with 
antipsychotic use, while depression significantly predicted use of antidepressants.  Patient 
sex and age were not significant predictors of any study medication (12).  Conversely, a 
more recent report did not find a significant association between disruptive behaviors and 
the use of any psychotropic medication, and instead found that having a greater number 
of co-morbid conditions and a fair/poor physical health rating independently increased 
the odds of antipsychotic medication use (10).  Results from studies with a broader focus 
on community-dwelling elderly were also inconclusive (4, 11, 14, 15), suggesting that the 
predictors of medication may change over time and thus vary over the course of disease. 
 55 
 
Although current work provides important insight into the predictors of 
psychotropic medication use among demented elderly living in the community, caregiver 
characteristics are consistently overlooked.  This is problematic because informal 
caregivers are key agents in the plan of care for elderly individuals with dementia.  
Furthermore, most studies in this area are cross-sectional and cannot evaluate whether the 
association between a particular risk factor and psychotropic medication changes over 
time as health declines and the risk of adverse drug events increases.  
Given these gaps in the literature, the goal of this study was to identify patient and 
caregiver characteristics that predict the use of three types of psychotropic medication 
(anxiolytics, antipsychotics, and antidepressants) and to determine whether the risk of 
psychotropic medication associated with these characteristics changes over time.  Using 
data from the Resources for Enhancing Alzheimer’s Caregiver Health (REACH) trial, we 
hypothesized that: 
(1) Caregiving burden and dementia patient symptoms would be associated 
with increases in psychotropic medication, whereas resources such as 
social network and positive aspects of caregiving would be associated with 
decreases in psychotropic medication use.  
(2) The association between care recipient symptoms such as problem 
behaviors and functional impairment, caregiver characteristics such as 
behavioral and impairment bother, and psychotropic medication use 
would be attenuated over time. 
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3.2 Methods 
Sample 
 The data were drawn from the Resources for Enhancing Alzheimer’s Caregiver 
Health I trial (ClinicalTrials.gov Identifier NCT00178165).  Recruitment procedures, 
eligibility criteria, and psychometric properties of all measures and intervention outcomes 
are described elsewhere (16, 17).  The primary goal of REACH I was to examine the 
feasibility and outcomes of multiple different intervention approaches aimed at 
improving Alzheimer’s Caregiver quality of life.  From 1996-2001, 1,222 community-
dwelling Alzheimer’s care recipients and their caregivers were recruited from six sites 
across the country (Birmingham, AL; Boston, MA; Memphis, TN; Miami, FL; Palo Alto, 
CA; and Philadelphia, PA) and randomized to either an active intervention or control.  
Single active interventions including skills training, telephone-linked computer system, 
and environmental skills building were used at three sites (Birmingham, Boston and 
Philadelphia, respectively) while the remaining sites implemented two active 
interventions: behavior and enhanced care (Memphis); family-based multisystem in-
home intervention (FMSII) and FSMII plus a computer integrated telephone system 
(Miami); and coping with caregiving instruction and an enhanced support group (Palo 
Alto).  Two sites used an information-only control condition (Boston and Philadelphia), 
one site provided information and referral services to the control group (Memphis), and 
the three remaining sites utilized an information and empathetic listening control 
(Birmingham, Miami, and Palo Alto).  Treatment was administered for 6 months.  
Caregivers in both the treatment and control groups were contacted for follow-up 
interviews at 6, 12, and 18 months after the initial assessment (16).  Only participants 
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with full baseline information on study variables and at least one complete follow-up 
assessment were included in the analyses (N=624).   
Outcome Measures 
This study focused on care recipient use of anxiolytic, antipsychotic, and 
antidepressant medications as the primary, dichotomous, outcome measures.  Information 
on medications was collected using the “brown bag” method of medication collection 
(18).  Accordingly, caregivers were asked to bring all currently administered medications 
to the in-person interview.  Medication names were recorded by study personnel and 
assigned a therapeutic classification code (19).  Although more detailed information on 
drug dosages and duration of use would have been desirable, these were not collected as 
the analysis of prescription medication was not a primary objective of the REACH trial. 
Independent Variables- Design Variables 
 Our analysis included caregiver/care recipient dyad characteristics that were used 
in designing the REACH intervention study.  These included categorical variables for 
caregiver sex and relationship to care recipient (spouse or non-spouse).  Caregiver 
racial/ethnic identity was also a design variable; however, it is highly correlated with care 
recipient race, a potential confounder in this study.  We therefore included care recipient 
racial/ethnic identity in place of caregiver racial/ethnic identity in the main analyses. 
Independent Variables- Predictor Variables 
This study considered several caregiver characteristics and care recipient 
symptoms as predictors of psychotropic medication use in the care recipient.  Primary 
variables of interest included care recipient baseline cognitive status as measured by the 
Mini-Mental State Examination (total scores range from 0 to 30, with higher scores 
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indicating better cognitive functioning; scores less than or equal to 24 indicate cognitive 
impairment) (20); care recipient functional status as measured by the ability to 
independently perform basic and instrumental activities of daily living (ADLs and IADLs 
respectively; possible scores ranged from 0 to 14 with higher scores indicating more 
functional impairment) (21); the extent to which a caregiver was bothered by assisting 
with functional limitations (daily care bother; final scores ranged from 0=not at all to 
4=extremely) (21); the presence of problem behaviors as measured by the Revised 
Memory and Behavior Problem Checklist (RMBPC) (scores range from 0-24 with higher 
scores indicating more problematic behaviors) (22); and the extent to which caregivers 
were bothered by the problem behaviors (final scores ranged from 0=not at all to 
4=extremely). 
Other variables of interest focused exclusively on the caregiver and include 
income adequacy, as measured by perceived difficulty with paying for basics (scores 
range from 1=not difficult at all to 4=very difficult); self-reported health (scores range 
from 1=poor to 5=excellent) (23);  depression, as measured by the 10-item version of the 
Center for Epidemiological Studies-Depression Scale (CES-D), (scores range from 0 to 
30, with higher scores indicating greater depressive symptomatology; scores of 16 or 
greater may indicate clinically significant depression) (24); vigilance, as measured by the 
hours per day a caregiver reported needing to be “on duty”  to care for the care recipient 
(25); positive aspects of caregiving, as measured by the nine-item Positive Aspects of 
Caregiving Scale (total scores ranged from 0 to 36, with higher scores indicating more 
positive appraisals of the caregiving situation) (26);  and social network size, as measured 
by the number of people who can be counted on to provide help (27).  
 59 
 
Potential Confounders and Effect Modifiers 
This study considered care recipient race (White, Black, Hispanic, Other), care 
recipient sex (male/female), and care recipient age at baseline, and intervention 
(treatment/control) (28) as potential confounders of the association between caregiver and 
care recipient characteristics and care recipient psychotropic medication use.  Time was 
hypothesized to be an effect modifier of the association between caregiver and care 
recipient characteristics and medication use, and was modeled as a categorical variable 
with four levels representing the baseline assessment, 6 month, 12 month, and 18 month 
follow-up assessments. 
Statistical Analysis 
Before addressing study hypotheses, a preliminary analysis was undertaken to 
determine whether participation in a REACH I active intervention reduced care recipient 
psychotropic medication use.  First, baseline descriptive statistics were calculated to gain 
a basic understanding of the distribution of demographic and medication risk factors in 
the treatment and control groups.  Randomization was checked with Chi-Square tests for 
discrete data and ANOVA for continuous variables.  Complete information on design 
variables, medication risk factors, and medication outcomes was available for 854 
randomized participants. To reduce the amount of missing data, we imputed 6-month 
medication values for participants who had matching medication values at baseline and 
12 months.  Twenty-one participants received an imputed medication values making 875 
participants available for analysis. 
The hierarchical structure of the REACH data (i.e. participants nested within sites 
with different interventions and control conditions) makes multilevel regression models a 
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natural choice for analysis; however, this method should be used with caution when the 
number of clustering units is small (fewer than 5 although conservative estimates report 
fewer than 30) (29, 30).  Multilevel models for these preliminary analyses using six 
clustering units did not converge, so generalized linear models with a logit link were used 
to determine whether participation in the active treatment group significantly reduced 
care recipient psychotropic medication use at the end of the 6-month intervention while 
controlling for site, design variables, and baseline care recipient medication use.  
Separate models were fit for anxiolytics, antipsychotics, and antidepressants. 
 To address the main study hypotheses, descriptive statistics were first computed 
for important baseline demographic variables.  Descriptive statistics were also computed 
for study predictors and outcomes at each assessment to examine general trends over 
time.  Generalized estimating equations with a logit link function and a first-order auto-
regressive covariance structure were used to assess the association between caregiver and 
care recipient characteristics and psychotropic medication use over the study period.   
Regression analyses for each outcome proceeded in multiple stages.  First, main-
effects models were constructed by examining the association between time, each 
predictor, and the odds of medication use, while controlling for site, design variables, and 
confounding variables.  We treated intervention as a confounder in these analyses to 
account for its association with caregiver attributes and attrition.  Predictors with a p-
value less than or equal to 0.10 were retained for use in the next stage of the analysis 
because it would be otherwise unlikely that a covariate would contribute to a 
multivariable model.  After the main-effects models were fit, two-way interactions 
between time, caregiver characteristics, and care recipient characteristics were tested and 
 61 
 
retained if they demonstrated significance at the 5% level.  In the final stage, predictors 
retained from the main effects model as well as significant interactions, design variables, 
confounders, and intervention were modeled together in a multivariable analysis.  
Estimates from the final, multivariable models were considered statistically significant at 
the 5% level.  A mathematical representation of the models used in this analysis is 
presented in section 3.5, Supplemental Equations. 
 Differential loss to follow-up was examined by comparing baseline demographic 
and risk factor distributions between participants with and without complete follow-up 
information using chi-square tests for categorical characteristics and ANOVA for 
continuous characteristics.  A sensitivity analysis was conducted by comparing results 
obtained from the multivariable models with all study participants to those obtained using 
only participants with complete follow-up information.  All analyses were performed 
using SAS software®, v. 9.2 (Cary, NC).   
3.3 Results 
 Results from the preliminary analysis of the REACH intervention are presented in 
Tables 3.1 and 3.2.  Table 3.1 displays the distribution of demographic and risk factor 
information for the treatment and control groups. Overall, randomization was successful 
in balancing the intervention groups as indicated by the similarity in the distribution of 
most of the demographic characteristics; however one demographic factor, race, and one 
potential medication risk factor, daily care bother, was significantly different across 
intervention groups at baseline. Table 3.2 presents the results from the analysis used to 
assess the intervention.  Active treatment was not a significant predictor of 6-month 
medication use for any study medication.  Baseline medication use was the most 
 62 
 
significant predictor of care recipient anxiolytic, antipsychotic, and antidepressant use at 
6 months (OR=37.35, 45.48, and 51.48 respectively, p<0.01).  A significant race effect 
was observed for anti-anxiety medication such that the odds of care recipient anxiolytic 
use during the intervention period were approximately two times higher for Hispanics 
compared to Whites (OR=2.26, p=0.03).  Hispanics were also more likely than Whites to 
use antipsychotic medication although the results were not statistically significant 
(OR=1.94, p=0.07). 
The sample used to assess the main study hypotheses included 654 REACH 
participants with complete baseline information and at least one complete follow-up 
assessment.  Of these participants, 278 (42.51%) completed all follow-up assessments.  
Reasons for missing follow-up information included death of the care recipient (N=84, 
12.84%), placement of the care recipient in a formal care facility (N=82, 12.54%), 
discontinuation in the study (N=85, 13.00%), and incomplete responses on study 
variables (N=125, 19.11%).  Caregivers with complete follow-up information 
experienced significantly less daily care bother than caregivers without complete 
information.  They were caring for individuals with significantly less cognitive and 
functional impairments, but more behavioral disruptions.  Baseline demographic 
information is presented in Table 3.3.  Caregivers in this study were, on average, 61 years 
old while care recipients were approximately 79 years of age.  A majority of caregivers 
and care recipients were female.  Over one-half of caregivers and care recipients were 
White, approximately 23% Black, and 20% Hispanic.  Participants with and without 
complete follow-up information did not differ by age; however, there were statistically 
significant differences in race and caregiver sex such that participants with full 
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information were less likely to be Black (versus White) and more likely to have female 
caregivers. 
Descriptive statistics for study predictors and outcomes for all participants by visit 
are presented in Table 3.4.  At baseline, care recipients experienced a moderate amount 
of cognitive and functional impairment.  The average total number of problematic 
behaviors exhibited by the care recipients in the past week was 10.11, causing caregivers 
“a little” to a “moderate” amount of bother.  Caregivers experienced substantially less 
bother managing functional impairments than behavioral disturbances. The average 
frequency of care recipient problematic behaviors and caregiver bother decreased slightly 
over the study period.  The prevalence of psychotropic medication use at baseline was 
high with half (50.46%) of participants taking at least one psychotropic medication.  
Approximately 18% of care recipients were using an anxiolytic or antipsychotic and 
nearly a third of care recipients were using an antidepressant.  Antidepressants were still 
the most prevalent psychotropic medication at the end of the follow-up period; however, 
the use of anxiolytics increased to 19.00% while the percent of care recipients using an 
antipsychotic increased to 24.00%. 
Analyses of All Study Participants 
Anxiolytics  
One hundred and sixteen care recipients were using an anxiolytic medication at 
baseline.  Of these people, 9 (7.76%) were also using an antipsychotic, 38 were using an 
antidepressant (32.76%).  Nine (7.76%) care recipients were using all three psychotropic 
medications.  Results from the bivariate analyses of anxiolytic medication use are 
presented in Table 3.5.  These results indicated that increases in care recipient functional 
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impairment and problematic behaviors were associated with slightly greater levels of care 
recipient medication use (OR=1.07, p=0.01 and OR=1.03, p=0.08 respectively).  
Caregiver characteristics including depression (OR=1.02, p=0.01), daily care bother 
(OR=1.28, p=0.06), and problem behavioral bother (OR=1.25, p<0.01) also exhibited a 
positive association with care recipient anxiolytic medication and were included in a 
multivariable model. 
 Results from the multivariable analysis of anxiolytic medication use including all 
654 study participants are presented in Table 3.6.  The odds of care recipient anxiolytic 
medication use were 2.41 times higher for Hispanics compared to Whites (OR=2.41, 
p<0.01).  Care recipient functional status was a significant predictor of anxiolytic 
mediation use such that every additional functional impairment increased the odds of 
medication use by 6% (OR=1.06, p=0.03).  Finally, a significant association between 
caregiver behavioral bother and care recipient anxiolytic medication use was also 
observed (OR=1.20, p<0.01) such that each additional unit of caregiver bother was 
associated with a 20% increase in medication use. 
Antipsychotics   
At baseline, 119 care recipients were using an antipsychotic medication.  Of these 
people, 18.49% (n=22) had concomitant anxiolytic use while 32.77% (n=39) had 
concomitant antidepressant use.  Nine care recipients (7.56%) were using all three 
psychotropic medications.  Results from the preliminary analyses of antipsychotic 
medication use presented in Table 3.5 revealed that decreased care recipient cognitive 
status and more functional impairments were associated with increases in care recipient 
antipsychotic use (OR=0.96, p<0.01 and OR=1.07, p<0.01 respectively).  Caregiver 
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depression exhibited a positive association with care recipient use of antipsychotic 
medication (OR=1.01, p=0.04).   
Results from the multivariable analysis of care recipient antipsychotic medication 
using all 654 study participants are displayed in Table 3.6.  As shown, intervention site 
was significantly associated with antipsychotic medication, as was relationship to the care 
recipient.  Patients under the care of a non-spousal caregiver were 52% less likely to use 
an antipsychotic medication (OR=0.48, p=0.02).   
Tests for the interaction between care recipient functional impairment and time 
indicated that the association between functional impairment and antipsychotic 
medication use was not constant across the study period (p=0.03).  We therefore 
calculated the effect of functional impairment at each study follow-up and examined the 
relative effect of a one-unit increase in functional impairment at each visit compared to 
baseline.  The highest odds of care recipient antipsychotic medication use associated with 
functional impairment was observed at baseline (OR=1.11, p<0.01); however, the odds 
decreased over the study time period (6 month follow-up: OR=1.06, p=0.05; 12 month 
follow-up: OR=1.01, p=0.75; 18 month follow-up: OR=1.01, p=0.87) (not shown due to 
space).   
The relative effect of functional impairment at each follow-up visit compared to 
baseline is shown in Table 3.6.  Although there is a positive association between 
functional impairment and care recipient medication use at each follow-up visit, the 
association is significantly attenuated over time.  For example, the odds of medication 
associated with each additional functional impairment at 6-months are 5% lower than the 
odds observed at baseline (OR=0.95, p=0.04).  Finally, a protective effect of cognitive 
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function was observed such that a one point increase in MMSE score reduced the odds of 
medication use by 3% (OR=0.97, p= 0.03).   
Antidepressants 
Two hundred and twelve care recipients were taking an antidepressant medication 
at baseline.  Of those, 38 (17.93%) were also taking an anxiolytic while 39 (18.40%) 
were taking an antipsychotic.  Nine (4.25%) care recipients were taking all three 
psychotropic medications.  The preliminary results displayed in Table 3.5 indicated that 
better care recipient cognitive status was associated with increases in antidepressant use 
(OR= 1.02, p=0.05) while perceived positive aspects of caregiving reduced the odds of 
antidepressant medication (OR=0.99, p=0.10). 
 Results from the multivariable analysis are presented in Table 3.6.  As shown, 
intervention site was the only significant predictor of antidepressant medication use in the 
multivariable model.  Higher levels of care recipient cognitive function and lower levels 
of perceived positive aspects of caregiving increased the odds of care recipient 
antidepressant use, however, the estimates were not statistically significant (OR=1.03 
p=0.06 ; OR=0.99, p=0.11 respectively).   
Sensitivity Analyses of Participants with Full Follow-up 
Anxiolytics 
Table 3.7 displays results for anxiolytics from the multivariable models using 
only participants with complete follow-up information.  Although the diminished power 
of this analysis resulted in non-statistically significant effects, many of the estimates 
obtained using only participants with complete follow-up were similar in direction and 
magnitude to the results obtained using all study participants with the exception of 
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intervention and race effects.  In the analysis including only individuals with full follow-
up, participation in the active treatment group reduced the odds of care recipient 
anxiolytic use by 3% (OR=0.97 in sensitivity analysis versus OR=1.59 in previous 
analysis with all study participants).  The increased odds associated with being Hispanic 
were attenuated in the analysis containing only individuals with full follow-up versus the 
analysis using all eligible participants (OR=1.81 in sensitivity analysis versus OR=2.41 in 
previous analysis with all study participants).  The odds ratios observed for functional 
impairment and behavioral bother in this analysis did not substantially differ from those 
obtained using participants with and without complete follow-up information. 
Antipsychotics 
Table 3.7 presents results from the multivariable models using only participants 
with complete follow-up information.  Although limiting the sample did not change the 
direction of the estimates, the magnitude of the effect was influenced in one case.  Care 
recipients under the care of a non-spousal caregiver were 80% less likely to use 
antipsychotic medications (OR=0.20 in sensitivity analysis versus OR=0.48 in previous 
analysis with all study participants).  Finally, estimates for cognitive status and the 
interaction between functional status and time were similar to estimates obtained using all 
participants, although the reduced power of this analysis resulted in statistically 
insignificant effects.   
Antidepressants 
Results antidepressant analyses obtained from participants with full follow-up 
information presented in Table 3.7.  Similar to the analysis including all participants, 
intervention site was one of the strongest predictors of antidepressant use.  Estimates of 
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the association between cognitive function and medication similar in magnitude and 
direction (OR=0.98 in sensitivity analysis versus 0.99 in previous analysis with all study 
participants), as were the estimates for positive aspects of caregiving (OR=1.02 in 
sensitivity analysis versus 1.03 in previous analysis with all study participants). 
3.4 Discussion 
 This study utilized longitudinal data from the REACH intervention to identify 
care recipient symptoms and aspects of caregiver appraisal that influence the use of 
anxiolytic, antipsychotic, and antidepressant medication use in community-dwelling 
dementia patients.  Our findings revealed that the use of psychotropic medication is 
influenced by the mental and physical condition of the care recipient and the subjective 
experience of the informal dementia caregiver.   
In accordance with study hypotheses, increases in caregiver behavioral bother 
were associated with higher odds of care recipient anxiolytic medication use; however, 
the frequency of problematic behaviors was not significantly associated with any study 
medication after inclusion in multivariable models.  These findings are consistent with 
Chan et al. but are in contrast with work that has identified hallucinations (12) and 
aggressive behaviors (11) as predictors of psychotropic drug use in community-dwelling 
dementia patients.  The lack of an observable association between problematic behaviors 
and psychotropic drug use in this study may be partially explained by the global nature of 
the behavior measurement instrument used in this study.  The RMBPC includes a wide 
range of problematic behaviors experienced in dementia and may not be sensitive enough 
to capture specific aggressive behaviors that would most likely be associated with 
psychotropic medication. 
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Another potential explanation may be the inclusion of caregiver characteristics in 
the current study.  Physicians rely on input from caregivers when assessing dementia 
patients and prescribing treatments.  Failure to include caregiver assessment may 
exaggerate the relation between dementia symptoms and psychotropic medication use 
found in other studies.  This explanation is supported by our data as problematic 
behaviors demonstrated a significant, positive association with anxiolytic use in 
preliminary analyses, but not in multivariable models that included caregiver burden. 
We also observed a positive association between care recipient functional 
impairment and the use of anxiolytic and antipsychotic medications, although the 
association observed for antipsychotics was significantly attenuated over the study 
period.  While functional impairment was not considered in several investigations of 
psychotropic medication use in community-dwelling elderly with dementia (12, 15, 31, 
32), our finding of a positive association between impairment and medication is 
consistent with work presented by Gustafsson et al. and Aparasu et al. (4, 33).  No 
significant association between functional impairment and psychotropic medication was 
reported by Chan et al. (10).  These discrepant findings may be explained, in part, by the 
variable relation between functional impairment and use of antipsychotic medication.  
Our findings suggest that antipsychotic medications are most widely used during the 
early and moderate stages of physical decline but are used more judiciously over time as 
the risk of adverse drug reactions increases. This pattern corresponds with guidelines 
established for other dementia medications such as cholinesterase inhibitors (34, 35).  
Consequently, cross-sectional studies of severely impaired community-dwelling dementia 
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patients may fail to find an association between functional impairment and antipsychotic 
use. 
Although not a main focus of this study, we evaluated whether the 6-month 
REACH intervention influenced care recipient psychotropic medication use.  Results 
indicated that the psychosocial interventions offered in REACH did not influence the use 
of any study medications; however, both the intervention and repeated measure analyses 
revealed potential racial and ethnic disparities in the pharmacologic management of 
dementia.  Although the role of culture and race/ethnicity has been largely ignored in the 
literature on psychotropic drug use in community dwelling dementia patients, our 
preliminary findings are commensurate with recently published work that found racial 
and ethnic disparities in the utilization of medications approved to treat cognitive 
symptoms of dementia (36).  Future work with a focus on recruiting minority dementia 
patients and caregivers is needed to understand whether racial/ethnic disparities in the 
treatment of dementia with psychotropic medication exist and whether care recipient 
symptoms and caregiver characteristics differentially influence psychotropic medication 
use across various racial/ethnic groups. 
The results of this study should be considered in light of the following limitations.  
First, the sample used for this study consisted of care recipients who were at the moderate 
to severe stage of dementia and had already experienced a substantial amount of 
cognitive and functional decline.  As a result, we were not able to capture the nature of 
the relation between functional impairment and care recipient psychotropic medication 
use across all stages of dementia.  Although analyses revealed that the effect of functional 
impairment on antipsychotic medication was attenuated over time, the odds ratio 
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associated with functional impairment was not significantly different from one at the 12 
or 18 month visit.  It is plausible that a more pronounced association between functional 
impairment and antipsychotic use would have been observed had participants been 
enrolled in earlier stages of disease.  Future studies utilizing longer follow-up periods and 
participants at various stages of dementia are needed to accurately characterize the role of 
functional impairment in care recipient psychotropic medication use. 
 Second, one must consider the possibility that the observed results are due to 
attrition bias.  Caregivers who remained in the study experienced significantly less daily 
care bother than caregivers who discontinued.  Therefore, it is possible that, in the 
presence of a true positive association between daily care bother and care recipient 
psychotropic medication use, the findings presented here are biased towards the null.  
Inferences regarding care recipient characteristics are also vulnerable to attrition bias.  
Care recipients completing all follow-up visits experienced significantly less cognitive 
and functional impairment than those without complete follow-up.  It is therefore 
possible that the observations concerning cognitive and functional impairment are also 
biased towards the null.  For example, the attenuated effect of functional impairment on 
antipsychotic medication use over time may have been more pronounced had care 
recipients with more severe functional impairment remained in the study.  A sensitivity 
analysis conducted only on individuals with complete follow-up suggests that the 
influence of attrition bias on the direction of study results is small.   
 Finally, information on medication dosages was not available in the REACH trial.  
Consequently, we are unable to comment on the extent to which care recipient and 
caregiver characteristics influence the intensity of psychotropic drug use in community-
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dwelling dementia patients.  It is conceivable that using a more sensitive measure of 
medication would identify associations that were not detected here.  Future work should 
include information on drug dosages in order to obtain a comprehensive picture of 
psychotropic medication use in community-dwelling dementia patients. 
 Despite the discussed limitations, this study provides valuable information 
regarding psychotropic drug use patterns among community-dwelling dementia patients 
in the United States.  To our knowledge, this is the first investigation to identify a 
variable association between functional impairment and antipsychotic medication use 
across time, suggesting that, despite the lack of formal guidelines that exist for FDA 
approved medications, physicians may be less likely to suggest pharmacologic treatment 
strategies as physical health declines.   
This study also identified caregiver behavioral bother as a risk factor for dementia 
patient anxiolytic medication use and as a result, emphasizes a comprehensive approach 
to dementia care.  Addressing the burden associated with managing problematic 
behaviors may be an effective way of reducing psychotropic medication use among 
elderly dementia patients residing in the community.  More work is needed to identify 
caregiver interventions that can successfully reduce care recipient medication use. 
 In conclusion, this study suggests that caregiver and care recipient characteristics 
are important predictors of psychotropic medication use in community-dwelling dementia 
patients, and that the risk of antipsychotic medication associated with care recipient 
functional impairment declines over time.  Reducing caregiver behavioral bother through 
the use of non-pharmacological interventions may be a reasonable strategy for decreasing 
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anxiolytic drug use among community-dwelling dementia patients while also improving 
caregiver quality of life.  
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3.5 Supplemental Equations 
The following equation is a mathematical representation of the generalized 
estimating equation used to assess study hypotheses (37). 
݈݋݃݅ݐ ൫ߨ௜௝൯ ൌ  ߙ ൅ ߚݔ௜௝+ eij 
Where ߨ௜௝ is the probability of medication for the ith care recipient at the jth time 
point ( j=0,1,2,3).   The errors, eij are assumed to have a multivariate normal distribution 
with mean 0 and variance Σ, where  
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Table 3.1 Baseline Demographic and Risk Factor Information for Intervention 
Analysis* 
 Treatment (N=558) Control (N=317) 
Caregiver variables   
  Race† (n,%)   
    White 301 (53.94) 180 (56.78) 
    Black 119 (21.33) 99 (31.23) 
    Hispanic 135 (24.19) 37 (11.67) 
    Other 3 (0.54) 1 (0.32) 
  Sex   
    Female 464(83.15) 250 (78.86) 
    Male 94 (16.85) 67 (21.14) 
  Age 61.31 (13.81) 62.25 (12.81) 
  Relationship to the care recipient (n,%)   
    Spouse 266 (47.67) 145 (45.74) 
    Non-spouse 292 (52.33) 172 (54.26) 
  Years providing care  4.30 (4.22) 4.50 (4.71) 
  Income adequacy 2.20 (1.06) 2.25 (1.07) 
  Depression  22.68 (8.42) 22.07 (7.83) 
  Daily care bother†  0.30 (0.55) 0.38 (0.61) 
  Behavioral bother  1.46 (0.91) 1.40 (0.88) 
  Social network 16.89 (4.70) 13.99 (4.99) 
Care recipient Variables   
  Race† (n,%)   
    White 299 (53.58) 178 (56.15) 
    Black 121 (21.68) 98 (30.91) 
    Hispanic 127 (22.76) 37 (11.67) 
    Other 11 (1.97) 4 (1.26) 
  Sex   
    Female 318 (56.99) 181 (57.10) 
    Male 240 (43.01) 136 (42.90) 
  Age 78.81 (11.03) 79.63 (7.80) 
  Cognitive status 12.92 (7.65) 12.45 (7.72) 
  Functional status 10.44 (2.77) 10.68 (2.91) 
  Number of problem behaviors 10.36 (4.16) 9.83 (4.04) 
*Information presented as mean (standard deviation) unless otherwise specified 
† p≤0.05 
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Table 3.2 Results from the REACH Intervention Analysis* 
 Anxiolytics Antipsychotics Antidepressants 
 Odds Ratio 95% Confidence 
interval 
Odds Ratio 95% Confidence 
interval 
Odds Ratio 95% Confidence 
interval 
Site       
  Philadelphia REF - REF - REF - 
  Birmingham 0.65 (0.26, 1.61) 0.98 (0.44, 2.18) 1.46 (0.66, 3.23) 
  Boston 0.94 (0.29, 3.02) 2.17 (0.83, 5.66) 0.79 (0.29, 2.17) 
  Memphis 0.96 (0.46, 1.96) 0.57 (0.27, 1.17) 1.08 (0.54, 2.15) 
  Miami 1.03 (0.26, 2.07) 1.36 (0.53, 3.51) 1.49 (0.61, 3.66) 
  Palo Alto 0.67 (0.20, 1.73) 0.72 (0.28, 1.81) 0.61 (0.26 1.47) 
Intervention       
  Control REF - REF - REF - 
  Treatment 0.93 (0.55, 1.55) 0.84 (0.52, 1.35) 0.87 (0.54, 1.40) 
Caregiver race       
  White REF - REF - REF - 
  Black 0.69 (0.31, 1.10) 1.41 (0.77, 2.61) 0.58 (0.31, 1.08) 
  Hispanic 2.01 (1.03, 4.18) † 1.94 (0.95, 3.93) 0.76 (0.38, 1.51) 
  Other 1.06 (1.05, 22.87) 0.79 (0.02, 30.39) 0.76 (0.02, 27.03) 
Caregiver sex       
  Female REF - REF - REF - 
  Male 0.67 (0.36, 1.27) 1.08 (0.59, 1.95) 1.00 (0.56, 1.81) 
Relationship to care 
recipient 
      
  Spouse REF - REF - REF - 
  Non-spouse 1.06 (0.64, 1.77) 0.98 (0.56, 1.48) 0.63 (0.39, 1.02) 
Daily care bother 1.39 (0.89, 2.18) 1.43 (0.92, 2.24) 1.14 (0.74, 1.77) 
Baseline medication§ 37.35 (23.14, 60.27)† 45.48 (27.97, 72.94)† 51.48 (34.92, 85.00)†
use     
*Estimates from generalized linear models controlling for study design variables including site, caregiver sex, caregiver race, 
relationship to the care recipient; also controlled for daily care bother, and baseline medication use 
†p≤0.05 
§Medication refers to the specific medication used in the model
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Table 3.3 Baseline Demographic Information for Analyses of Main Study 
Hypotheses  
Demographic 
Variables 
All  
(N=654) 
Full Information 
(N=278) 
Incomplete Information 
(N=376) 
Age at baseline, Mean (SD)    
  Caregiver 60.99 (13.48) 60.52 (13.63) 61.33 (13.37) 
  Care recipient 79.31 (9.49) 78.35 (11.06) 80.03 (8.07) 
Race, n (%)    
  Caregiver*    
    White 361 (55.20) 159 (57.19) 202 (53.72) 
    Black 150 (22.94) 42 (15.11) 108 (28.72) 
    Hispanic 140 (21.41) 76 (27.34) 64 (17.02) 
    Other 3 (0.46) 1 (0.36) 2 (0.53) 
Care recipient*    
    White 361 (55.20) 160 (57.55) 201 (53.46) 
    Black 152 (23.24) 45 (16.19) 107 (28.46) 
    Hispanic 132 (20.18) 69 (24.82) 63 (16.76) 
    Other 9 (1.38) 4 (1.44) 5 (1.32) 
Sex, n (%)    
  Caregiver*    
    Male 111 (16.97) 37 (13.31) 74 (19.68) 
    Female 543 (83.03) 241 (86.69) 302 (80.32) 
  Care recipient    
    Male 273 (41.74) 126 (45.32) 147  (39.10) 
    Female 381 (58.26) 152 (54.68) 229 (60.90) 
Relationship to the care 
recipient, n (%) 
   
  Spouse 289 (44.19) 132 (47.48) 157 (41.76) 
  Non-Spouse 365 (55.81) 146 (52.52) 219 (58.24) 
Years providing  
care, Mean (SD) 
4.45 (4.57) 4.37 (4.82) 4.50 (4.38) 
*p≤0.05 for chi-square test of homogeneity
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Table 3.4 Descriptive Statistics for Study Predictors and Outcomes by Visit for All Participants* 
 
Study predictors and outcomes 
 
Range† 
 
Baseline 
(n=654) 
 
6 month 
follow-up 
(n=628) 
 
12 month  
follow-up  
(n=363) 
 
18 month  
follow-up 
(n=300) 
Care recipient symptoms      
  Cognitive status 0-30 13.35 (7.59) X X X 
  Functional status 0-14 10.41 (2.87) 10.96 (2.81) 11.03 (2.81) 11.25 (2.76) 
  Number of problem behaviors    
    Endorsed 
0-24 10.11 (4.06) 9.47 (4.14) 9.56 (4.06) 9.71 (4.33) 
Caregiver attributes      
  Income adequacy 0-3 2.21 (1.06) 2.16 (1.05) 2.09 (1.05) 2.16 (1.08) 
  Overall current health 1-5 2.98 (1.05) 2.92 (1.04) 3.00 (1.06) 2.93 (1.06) 
  Caregiver depression 0-30 14.95 (11.01) 14.28(10.61) 13.87 (10.89) 13.21 (9.97) 
  Daily care bother 0-4 0.28 (0.53) 0.30 (0.58) 0.20 (0.47) 0.20 (0.51) 
  Problem behavioral bother 0-4 1.43 (0.89) 1.35 (0.90) 1.29 (0.88) 1.26 (0.84) 
  Vigilance 0-24 18.27 (7.73) 18.50 (7.59) 18.23 (7.75) 18.44 (7.64) 
  Positive aspects of caregiving 0-36 34.35 (8.81) 34.66 (9.07) 34.94 (8.96) 35.44 (8.00) 
  Social network 0-30 16.69 (5.52) 16.59 (5.54) 16.87 (5.14) 16.96 (5.44) 
Outcomes, n (%)       
  Anxiolytics - 116 (17.74) 115 (18.31) 64 (17.63) 57 (19.00) 
  Antipsychotics - 119 (18.20) 122 (19.56) 84 (23.14) 72 (24.00) 
  Antidepressants - 212 (32.42) 197 (31.37) 120 (33.06) 96 (32.00) 
*All values are presented as means and standard deviations, except where otherwise noted 
†Range of the measurement instrument  
SD=standard deviation 
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Table 3.5 Results From Preliminary Analyses Examining the Association Between Each Predictor, and the Odds of Medication 
Use* 
 Anxiolytics Antipsychotics Antidepressants 
Variable Odds 
Ratio 
95% Confidence 
interval 
Odds 
Ratio 
95% Confidence 
interval 
Odds 
Ratio 
95% Confidence 
interval 
Care recipient symptoms       
  Cognitive status 0.99 (0.97, 1.01) 0.96 (0.94, 0.99)† 1.02 (1.00, 1.04) † 
  Functional status 1.07 (1.02,   1.13)† 1.07 (1.02, 1.12)† 0.99 (0.97, 1.03) 
  Number of problem behaviors 1.03 (1.00, 1.06)† 1.01 (0.99, 1.04) 1.00 (0.98, 1.03) 
Caregiver attributes       
  Income Adequacy 1.03 (0.92, 1.16) 1.03 (0.92, 1.14) 1.03 (0.94, 1.12) 
  Overall current health 0.58 (0.84, 1.07) 1.00 (0.90, 1.10) 0.97 (0.89, 1.05) 
  Caregiver depression 1.02 (1.00, 1.03)† 1.01 (1.00, 1.02)† 1.00 (1.00, 1.01) 
  Daily care bother 1.28 (0.99, 1.66)† 1.15 (0.91, 1.45) 1.16 (0.94, 1.43) 
  Problem behavioral bother 1.25 (1.11, 1.40)† 1.06 (0.95, 1.19) 1.03 (0.94, 1.13) 
  Vigilance 1.00 (0.99, 1.01) 1.00 (0.99, 1.01) 1.00 (0.99, 1.01) 
  Positive aspects of caregiving 0.99 (0.98, 1.00) 0.99 (0.97, 1.00) 0.99 (0.98, 1.00) † 
    Social network 0.99 (0.97, 1.01) 0.99 (0.97, 1.01) 1.00 (0.98, 1.02) 
* Estimates from generalized linear models controlling for site, intervention assignment, caregiver relationship to the care recipient, 
caregiver sex, care recipient sex, care recipient race, and care recipient age at baseline 
†p≤0.10 
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Table 3.6 Results From Multivariable Analyses Including All Study Participants* 
 Anxiolytics Antipsychotics Antidepressants 
Variable Odds Ratio 95% Confidence 
Interval 
Odds Ratio 95% Confidence 
Interval 
Odds Ratio 95% Confidence 
Interval 
Intervention       
  Control REF - REF - REF - 
  Treatment 1.59 (1.07   2.37)† 0.88 (0.60, 1.28) 0.91 (0.66, 1.27) 
Site       
  Philadelphia REF - REF - REF - 
  Birmingham 1.52 (0.71, 3.26) 2.93 (1.56, 5.53)† 1.47 (0.78,  2.81) 
  Boston 0.50 (0.20, 1.50) 1.58 (0.62, 4.04) 1.03 (0.51, 2.08) 
  Memphis 1.18 (0.64, 2.17) 1.59 (0.90, 2.81) 1.66 (1.00, 2.76)†
  Miami 1.32 (0.67, 2.56) 1.67 (0.88, 3.18) 2.01 (1.14, 3.53)†
  Palo Alto 0.642 (0.34, 1.23) 0.90 (0.49, 1.68) 0.91 (0.54,1.51) 
Relationship to care 
recipient 
      
  Spouse REF - REF - REF - 
  Non-spouse 1.15 (0.64, 2.10) 0.48 (0.25, 0.91)† 0.96 (0.58, 1.60) 
Caregiver sex       
  Female REF - REF - REF - 
  Male 1.02 (0.56, 1.88) 0.61 (0.31, 1.21) 0.82 (0.48, 1.39) 
Care recipient sex       
  Female  REF - REF - REF - 
  Male 1.24 (0.69, 2.27) 0.75 (0.41, 1.39) 0.77 (0.47, 1.28) 
Care recipient race       
  White REF - REF - REF - 
  Black 0.71 (0.43, 1.22) 1.20 (0.74, 1.96) 0.68 (0.44, 1.06) 
  Hispanic 2.41 (1.49, 3.91)† 1.41 (0.86, 2.31) 0.65 (0.40, 1.04) 
  Other 0.41 (0.05, 3.50) 1.82 (0.41, 8.12) 0.52 (0.14, 1.87) 
Baseline age 1.01 (0.99, 1.03) 1.00 (0.98, 1.02) 0.98 (0.96, 1.00) 
       
  
 
81
Table 3.6 continued 
 Anxiolytics Antipsychotics Antidepressants 
Variable Odds Ratio 95% Confidence 
Interval 
Odds Ratio 95% Confidence 
Interval 
Odds Ratio 95% Confidence 
Interval 
Visit       
  Baseline REF - REF - REF - 
  6-month 1.01 (0.83, 1.22) - - 0.98 (0.86, 1.11) 
  12-month 0.97 (0.78, 1.21) - - 1.02 (0.87, 1.20) 
  18-month 1.18 (0.93, 1.50) - - 0.95 (0.81, 1.13) 
Cognitive status - - 0.97 (0.95, 0.99)† 1.02 (1.00, 1.04) 
Functional status 1.06 (1.01, 1.12)† - - - - 
Functional status*visit      
  Functional status      
    Baseline - - REF - - - 
    6-month - - 0.95 (0.90, 1.00)† - - 
    12-month - - 0.90 (0.85, 0.97)† - - 
    18-month - - 0.90 (0.83, 0.98) † - - 
Daily care bother 1.14 (0.88, 1.47) - - - - 
Problem behavior 
frequency 
1.00 (0.97, 1.03) - - - - 
Problem behavioral bother 1.20 (1.05, 1.36)† - - - - 
Caregiver depression 1.01 (1.00, 1.02) 1.01 (1.00, 1.02) - - 
Positive aspects of 
caregiving 
- - - - 0.99 (0.98, 1.00) 
* Estimates from generalized linear models controlling for site, intervention assignment, caregiver relationship to the care recipient, 
caregiver sex, care recipient sex, care recipient race, and care recipient age at baseline 
†p≤0.05 
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Table 3.7 Results From Multivariable Analyses for Participants With Full Follow-Up Information* 
 Anxiolytics Antipsychotics Antidepressants 
Variable Odds Ratio 95% Confidence 
Interval 
Odds Ratio 95% Confidence 
Interval 
Odds Ratio 95% Confidence 
Interval 
Intervention       
  Control REF - REF - REF - 
  Treatment 0.97 (0.48, 1.99) 0.42 (0.23,  0.78) 0.98 (0.56, 1.71) 
Site       
  Philadelphia REF - - - - - 
  Birmingham 1.84 (0.43, 7.82) 1.27 (0.41, 3.97) 1.97 (0.67, 5.81) 
  Boston 0.21 (0.02, 1.95) 1.23 (0.32,  4.70) 0.99 (0.31, 3.16) 
  Memphis 1.29 (0.34, 4.86) 1.45 (0.51,  4.09) 1.66 (0.62, 4.39) 
  Miami 1.57 (0.39, 6.28) 1.35 (0.47, 3.87) 2.38 (0.83, 6.82) 
  Palo Alto 1.22 (0.32, 4.65) 0.86 (0.31,  2.40) 0.84 (0.32, 2.18) 
Relationship to care 
recipient 
      
  Spouse REF - REF - REF - 
  Non-spouse 0.73 (0.22, 2.35) 0.20 (0.06,  0.67) 1.46 (0.58, 3.69) 
Caregiver sex       
  Female REF - REF - REF - 
  Male 0.80 (0.25, 2.58) 0.44 (0.13, 1.48) 0.64 (0.23, 1.75) 
Care recipient sex       
  Female  REF - REF - REF - 
  Male 0.77 (0.25, 2.36) 0.33 (0.10, 1.02) 0.75 (0.31, 1.85) 
Care recipient race       
  White REF - REF - REF - 
  Black 0.43 (0.14, 1.34) 1.78 (0.82, 3.88) 0.47 (0.22, 1.02) 
  Hispanic 1.81 (0.90, 3.62) 1.57 (0.76, 3.22) 0.54 (0.28, 1.06) 
  Other 0.82 (0.11, 6.11) 5.64 (0.88, 36.18) 0.14 (0.03, 0.72) 
Baseline age 1.02 (0.99, 1.05) 1.00 (0.98, 1.03) 0.98 (0.95, 1.01) 
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Table 3.7 continued 
 Anxiolytics Antipsychotics Antidepressants 
Variable Odds Ratio 95% Confidence 
Interval 
Odds Ratio 95% Confidence 
Interval 
Odds Ratio 95% Confidence 
Interval 
Visit       
  Baseline REF - - - - - 
  6-month 0.91 (0.67, 1.22) - - 0.95 (0.80, 1.15) 
  12-month 1.05 (0.77, 1.43) - - 1.04 (0.85, 1.29) 
  18-month 1.26 (0.90, 1.73) - - 0.95 (0.76, 1.19) 
Cognitive status - - 0.99 (0.88, 1.07) 1.02 (0.99, 1.05) 
Functional status 1.01 (0.94, 1.10) - - 1.02 (0.99, 1.05) 
Functional status*visit      
  Functional status      
    Baseline - - REF - - - 
    6-month - - 0.98 (0.93, 1.05) - - 
    12-month - - 0.97 (0.89, 1.05) - - 
    18-month - - 0.97 (0.96, 1.13) -  
Daily care bother 1.10 (0.94, 1.29) - - - - 
Problem behavior 
frequency 
1.01 (0.96, 1.05) - - - - 
Problem behavioral bother 1.10 (0.94, 1.29) - - - - 
Caregiver depression 1.00 (0.98, 1.02) 1.00 (0.99,  1.02) - - 
Positive aspects of 
caregiving 
- - - - 0.98 (0.97, 0.99) 
* Estimates from generalized linear models controlling for site, intervention assignment, caregiver relationship to the care recipient, 
caregiver sex, care recipient sex, care recipient race, and care recipient age at baseline†p≤0.05 
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Chapter 4  
 
Racial and Ethnic Disparities in Psychotropic Medication Use Among Community-
Dwelling Dementia Patients 
 
4.1 Background 
There are currently two classes of medications approved by the FDA for the 
treatment of Alzheimer’s disease and related disorders: cholinesterase inhibitors for the 
early to moderate stages of dementia, and NMDA receptor antagonists for moderate to 
severe disease stages.  These medications are primarily used to delay the progression of 
cognitive symptoms (1).  Previous investigations of approved anti-dementia medications 
have uncovered racial/ethnic differences in drug utilization with non-Hispanic White 
patients receiving more prescriptions for anti-dementia treatments relative to minority 
patients (2-5).  This difference is particularly concerning considering that older African 
Americans and Latinos are part of the fastest growing sector of the US elderly population 
and are more likely than older Caucasians to have Alzheimer’s disease and other 
dementias (6, 7). 
A wide variety of psychotropic medications including anxiolytics, antipsychotics, 
and antidepressants are also used in the treatment of dementia.  Although not approved 
by the FDA, these medications are often prescribed off-label to manage mood and 
behavioral symptoms (8).  Compared to FDA approved dementia medications, relatively 
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little is known about the patterns of psychotropic medication in minority dementia 
patients and whether racial/ethnic disparities exist.  A majority of the existing work in 
this area focuses on relatively homogeneous nursing home populations and cannot be 
generalized to people residing in the community (9-15).  Few studies of psychotropic 
medication use among elderly people living in the community exist (16-20), and only a 
small portion focus exclusively on elderly with dementia.  Among investigations that do 
examine the use of psychotropic medications by community-dwelling dementia patients, 
a comprehensive evaluation of potential racial/ethnic differences is not possible due to 
either the absence of race/ethnicity data in the analysis (21, 22) or the dichotomization of 
race into White and non-White categories (White versus Black, White versus Other)   
(23).  None of the published literature focusing on community-dwelling dementia patients 
has examined the patterns of psychotropic medication use specifically within community-
dwelling Hispanics/Latinos with dementia.  This omission represents a considerable 
knowledge gap as a disproportionate share of Hispanic/Latino dementia patients reside in 
the community and are cared for by relatives (24, 25).   
Typically, differential access and utilization of health care and differences in 
health outcomes by a demographic group is considered a health disparity.  Within the 
areas of public health and social sciences, the term “disparity” may also carry with it a 
connotation of injustice based on the view that health inequalities are unnecessary and 
avoidable (26) .  Disparities can exist across several demographic groups including age, 
sex, and race/ethnicity.  In many situations, the consequence of a disparity is clear.  For 
example, influenza vaccination rates are substantially lower in elderly Black/African 
Americans and Hispanic/Latinos compared to elderly White/Caucasians (27).  This 
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disparity represents a clear disadvantage for minority elders as influenza vaccines are 
highly effective at reducing morbidity and mortality associated with influenza (27). 
Consequences of disparities in psychotropic medication use among community-
dwelling dementia patients are not as straightforward.  Although psychotropic 
medications demonstrate some efficacy in reducing mood and behavioral disturbances in 
dementia, they are also associated with substantial risks (28-30).  It is therefore unclear 
whether racial/ethnic differences in psychotropic medication use necessarily represent a 
disadvantage for the demographic groups receiving the least medication.  Consequently, 
we will refer to differences in the use of psychotropic medication across race as 
racial/ethnic disparities in medication use without implying a direction of disadvantage.   
Multiple conceptual models are available to help understand the determinants of 
psychotropic medication use in dementia caregiving and also to understand how 
racial/ethnic disparities in medication use arise (31-33).  These models highlight the 
multifactorial nature in which race/ethnicity can influence caregiving outcomes including 
differential exposure to hazards or stressors that influence health and exacerbate disease; 
unequal access to financial and educational resources that buffer the effects of stressors; 
and variability in cultural norms that influence perceptions of caregiving, coping 
strategies, and social support availability.  Although conceptual models provide a useful 
framework for thinking about how race/ethnicity influences health outcomes, it is often 
difficult to find data sources that are able to address all model components.  A majority of 
the existing work on racial/ethnic differences in anti-dementia medication among 
community-dwelling elderly people relies on billing data (34) or cohorts of elderly people 
that focus solely on the care recipient, thereby lacking information on informal caregivers 
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(2, 3, 5).  Informal caregivers are key agents for the plan of care for elderly individuals 
with dementia, and caregivers from different racial/ethnic groups may vary in the 
perceived intensity of stressors and coping strategies that are relevant to health outcomes 
(35).  For example, the use of spiritual religious coping mechanisms by African 
American caregivers combined with cultural perceptions of caregiving likely influence 
the decision of whether or not to initiate psychotropic medication (36).  The extent to 
which caregiver characteristics influence care recipient psychotropic medication in 
minority populations and whether caregiver characteristics account for differences in 
medication use across diverse populations is unknown. 
Given the gaps in the literature surrounding the use of psychotropic medication in 
diverse groups of community-dwelling dementia patients, we first focused on 
documenting racial/ethnic disparities in the use of three psychotropic medications 
(anxiolytics, antipsychotics, and antidepressants).  We then identified variables that 
explained racial/ethnic disparities in psychotropic medication as potential targets for 
future interventions.  Using data from the Resources for Enhancing Alzheimer’s 
Caregiver Health (REACH) II randomized trial, we hypothesized that  
(1) The prevalence of psychotropic medication would be higher in non-
Hispanic Whites compared to Hispanics/Latinos or Black/African 
Americans, and 
(2) Observed differences between racial/ethnic groups would be explained 
by, caregiver socioeconomic factors, care recipient characteristics, 
caregiver health, perceptions of caregiving, or non-financial resources. 
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Given the lack of data regarding the predictors of psychotropic medication within 
minority, community-dwelling, dementia patients, another goal was to examine 
predictors of care recipient psychotropic medication within racial/ethnic groups.  This 
information will give clinicians a better understanding of the needs of the patients and 
caregivers they serve, and may also help inform future interventions aimed at decreasing 
off-label use of psychotropic medications. 
4.2 Methods 
Sample 
The data for this study were drawn from the baseline assessment of REACH II 
(ClinicalTrials.gov Identifier NCT00177489).  Recruitment procedures, eligibility 
criteria, and psychometric properties of all measures and intervention outcomes are 
described elsewhere (37).  The primary goal of the REACH II trial was to evaluate a 
multi-component, psychosocial intervention aimed at improving the quality of life of 
Alzheimer’s caregivers.  In total, 642 community-dwelling Alzheimer’s care recipients 
and their caregivers were recruited throughout 2001-2004 from five sites across the 
country (Birmingham, AL; Memphis, TN; Miami, FL; Palo Alto, CA; and Philadelphia, 
PA).  This analysis included only caregivers who were the same race/ethnicity as the care 
recipients.  All participants needed to have full information on study predictors and 
outcome (N=543). 
Outcome Measures 
 This study focused on care recipient use of anxiolytic, antipsychotic, and 
antidepressant medications as the primary outcome measures.  Information on 
medications was collected using the “brown bag” method of medication collection (38).  
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Accordingly, caregivers were asked to bring all currently administered medications to the 
in-person interview.  Medication names were recorded by study personnel and assigned a 
therapeutic classification code (39).  Although more detailed information on drug dosages 
and duration of use would have been desirable, these were not collected as the analysis of 
prescription medication was not a primary objective of the REACH II trial. 
Predictors 
Several caregiver and care recipient characteristics were examined as predictors 
of care recipient psychotropic medication use.  Care recipient race, the focal variable of 
this study, was obtained through caregiver report and recorded as either non-Hispanic 
White, Hispanic/Latino, or Black/African American.  Sampling was clustered by study 
site and was therefore also considered in the investigation.  Other variables of interest 
reported by the caregiver included socioeconomic status as measured by current 
employment status (unemployed, retired, homemaker, employed), years of education, 
yearly household income before taxes, and income adequacy as measured by difficulty 
paying for basics (scores range from 1=not difficult at all to 4=very difficult). 
Several care recipient characteristics were also used in this investigation and 
included baseline cognitive status as measured by the Mini-Mental State Examination 
(total scores range from 0 to 30, with higher scores indicating better cognitive 
functioning; scores less than or equal to 24 indicate cognitive impairment) (40); 
functional impairment as measured by the ability to independently perform basic and 
instrumental activities of daily living (ADLs and IADLs respectively; possible scores 
ranged from 0 to 14 with higher scores indicating more functional impairment) (41); and 
the number of behavioral disturbances exhibited in the past week as measured by the 
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Revised Memory and Behavior Problem Checklist (RMBPC) (scores range from 0-24 
with higher scores indicating more problematic behaviors) (42).   
No direct measure of pain was collected in REACH II; however, information on 
care recipient analgesic medication use was available.  Previous research supports the use 
of analgesic medication as a proxy for pain (43) ; therefore, care recipient use of a 
narcotic or COX-2 inhibitor was utilized as a dichotomous surrogate for pain.  Non-
steroidal anti-inflammatory agents (NSAIDs) were not considered here as they have 
historically been used to manage low levels of chronic pain that cannot necessarily be 
eliminated (44). Additionally, NSAIDs such as aspirin are often used to decrease platelet 
aggregation and prevent blood clots (45).  An overwhelming majority of the NSAID use 
in this study was aspirin (84.2%). Therefore, we focused on the presence of a narcotic or 
COX-2 inhibitor as surrogate for pain.  Care recipient sex (male/female), age at baseline, 
and relationship to the caregiver (spouse/non-spouse) were also considered.   
Several variables representing caregiver perceptions of caregiving were used in 
the analyses and included overall caregiving burden as measured by an abbreviated, 12-
item version of the Zarit Caregiver Burden Inventory (total scores range from 0 to 48, 
with higher scores indicating greater burden) (46, 47); the extent to which a caregiver 
was bothered by assisting with care recipient functional limitations (daily care bother; 
final scores ranged from 0=not at all to 4=extremely) (48); the extent to which caregivers 
were bothered by care recipient problem behaviors (final scores ranged from 0=not at all 
to 4=extremely) (42); the amount of confidence caregivers had in handling the problem 
behaviors (final scores ranged from 0=not at all to 4=extremely)  (42); caregiving 
mastery, assessed by eight items developed by REACH investigators (total scores ranged 
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from 0 to 16 with lower scores indicating greater mastery) (49); vigilance, measured by 
the hours per day a caregiver reported needing to be “on duty”  to care for the care 
recipient (49); and positive aspects of caregiving, measured by the nine-item Positive 
Aspects of Caregiving Scale (total scores ranged from 0 to 36, with higher scores 
indicating more positive appraisals of the caregiving situation (50).  
The final caregiver characteristics we considered were health and non-financial 
resources.  Health was measured by self-report (both current and current versus six 
months previous; scores range from 0-5 with higher scores indicating poorer health) (51) 
and depression, as measured by the 10-item version of the Center for Epidemiological 
Studies-Depression Scale (CES-D), (scores range from 0 to 30, with higher scores 
indicating greater depressive symptomatology; scores of 16 or greater may indicate 
clinically significant depression) (52).  Non-financial resources were captured by spiritual 
and religious coping resources and social network resources.  Spiritual and religious 
coping was assessed by nine questions asking caregivers to rate the extent to which 
religious and spiritual beliefs affect their caregiving (total scores ranged from 0 to 18 
with higher scores indicating greater spiritual and religious coping) (53); while multiple 
dimensions of social support including network size, support satisfaction, and negative 
social interactions were captured from several previous measures of social interaction and 
support (54-56). Social network size was assessed with two questions regarding the 
number of people who can be counted on to provide help.  Total scores range from 0 to 
10 with higher scores indicating larger social networks. Caregiver satisfaction with the 
help received from social contacts was assessed with three questions.  Total scores range 
from 0 to 9, with higher scores indicating more satisfaction.  Finally, the presence of 
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negative social interactions was assessed with four questions asking caregivers to rate the 
frequency of negative interactions on a four-point scale.  Total scores ranged from 0-12 
with higher scores indicating a greater frequency of negative social interactions.  The 
final resource considered was dementia knowledge measured by the caregiver’s general 
knowledge of memory loss, dementia, and end of life legal issues (total scores range from 
0 to 4, with higher scores indicating greater knowledge of dementia and dementia related 
issues) (49).  
Statistical Analysis 
Descriptive statistics were computed for important demographic variables to 
provide a basic understanding of sample characteristics.  To determine whether there 
were racial/ethnic disparities in the use of psychotropic medication, generalized linear 
models with a logit link function were fit using each medication as an outcome and 
race/ethnicity as a predictor.  Two common methods used in the epidemiologic literature 
were considered for evaluating explanations for racial/ethnic disparities in psychotropic 
medication use, including successive addition of variables that may attenuate the effect of 
race and the addition of interaction terms to determine whether the risk of medication 
associated with a variable of interest differs across race. 
For several reasons, these methods were considered insufficient for the current 
study.  First, the explanatory variable sets in this investigation do not have a natural 
hierarchical structure, making it difficult to successively add variable sets that may 
explain the race effect.  Second, two-way interactions with race in this context would, for 
example, provide information on whether the risk of medication associated with socio-
economic status varies by race.  The absence of an interaction, however, does not imply 
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that the effect of race is not explained by socioeconomic status.  Racial/ethnic disparities 
in psychotropic medication may be due to differences in the distribution of 
socioeconomic status across race.  Additionally, examining the interaction between race 
and socioeconomic status would require multiple interaction terms to account for the 
several variables that address socioeconomic status.  Our study did not have enough 
power to evaluate two-way interactions between each potential explanatory variable and 
race.  Consequently, we chose to address study hypotheses concerning differing patterns 
of medication use between racial/ethnic groups using AIC model selection, an 
information-theoretic approach presented by Burnham and Anderson (57).  This approach 
allowed us to determine whether observed racial/ethnic disparities in psychotropic 
medication use could be explained by caregiver socioeconomic status, care recipient 
characteristics, caregiver perceptions of caregiving, caregiver health, or non-financial 
caregiving resources.  Site was also considered due to the clustered nature of the sample.  
The AIC model selection approach has been used extensively in the ecology literature 
and has recently been recognized in the social sciences as a theoretically rigorous method 
for selecting an optimal model from various pre-specified models (58).   
Briefly, this method uses Akaike Information Criterion (AIC) to quantify the 
amount of information in a given set of pre-specified models relative to the amount of 
noise.  To facilitate comparison of models, AIC values are often rescaled such that the 
model with the minimum AIC has a value of zero.  This model is the AIC minimal model 
and the most optimal.   Remaining models are then ranked based on the rescaled AIC 
(lower is better) and compared to the minimum AIC model based on the differences in 
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AIC (ΔAIC), with large values of ΔAIC (typically greater than 2) providing little support for 
the non-minimal AIC model (57, 58). 
Differences in model AIC can also be used to calculate the likelihood of a model 
given the data.  These likelihoods represent the strength of evidence for each model.  
Typically, these likelihoods are normalized to be a set of positive Akaike weights that 
sum to one.  Evidence ratios are then calculated from the weights by dividing the weight 
of a given model by the weight of the other model of interest.  These ratios represent the 
relative strength of evidence for one model versus the other, and quantify the amount of 
variation in the selected best model from sample to sample if we could draw repeated, 
independent samples from the population.  Evidence ratios close to one indicate that there 
is little evidence in favor of either model and suggests that we would observe a large 
amount of variation in the selected best model from sample to sample (57, 58).   
Given our a priori interest in care recipient characteristics, caregiver 
socioeconomic status, caregiver perceptions of caregiving, caregiver health, and non-
financial caregiving resources, we employed this approach to determine whether models 
containing some combinations of these variable sets without race were more 
parsimonious that the equivalent model containing race, thus implying that racial/ethnic 
disparities in psychotropic medication can be explained by these other factors.  All 
combinations of variable sets were investigated in main effects models to determine 
whether certain sets contained relatively more information on the medication outcomes of 
interest.   
Separate analyses were performed to investigate predictors of psychotropic 
medication use within racial/ethnic groups.  For these analyses, data were stratified by 
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race and preliminary logistic regression models were used to examine the association 
between each predictor and the odds of medication use, while controlling for site, 
caregiver relationship to the care recipient, caregiver education, care recipient age, and 
care recipient sex.  Predictors with a p-value less than or equal to 0.10 were retained for 
use in the next stage of the analysis because it would be otherwise unlikely that a 
covariate would contribute to a multivariable model.  All predictors retained from the 
preliminary analyses were then included in multivariable models that also controlled for 
site, caregiver relationship to the care recipient, caregiver education, care recipient age, 
and care recipient sex.  Income demonstrated a strong, positive correlation with education 
in each racial/ethnic group and was therefore not included as an additional confounder.  
Based on previous observations that predictors of psychotropic medication vary across 
medication type (16), analyses were performed separately for anxiolytics, antipsychotics, 
and antidepressants.  Estimates from the multivariable models were considered 
statistically significant at the 5% level. 
4.3 Results 
Demographic characteristics of the REACH II participants are shown in Table 
4.1.  As shown in Table 4.2, care recipients across racial/ethnic groups exhibited, on 
average, approximately eleven behavioral disturbances, causing caregivers “a little” to “a 
moderate” amount of bother.  On average, White and Black caregivers reported “very 
much” confidence managing behavioral disturbances whereas Hispanic caregivers 
reported only “moderate” levels of confidence.  Figures 1 and 2 display the distribution 
of care recipient psychotropic medication use for each racial/ethnic group.  As shown in 
Figure 4.1, antidepressants were the most prevalent psychotropic medication across all 
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racial groups, followed by antipsychotics, and anxiolytics.  Within White/Caucasian care 
recipients the percentage of people taking an antipsychotic is slightly over two times the 
percentage taking an anxiolytic; however, that relation does not hold within 
Black/African American care recipients where the prevalence of anxiolytics is almost 
equal to that of antipsychotics.  Within Hispanic/Latino care recipients, the prevalence of 
antipsychotic use is approximately 1.5 times greater than the use of anxiolytics.  
The distribution of the number of psychotropic medications taken by care 
recipients is displayed in Figure 4.2.  Hispanics demonstrate the lowest prevalence of 
psychotropic medication use with approximately 48% of care recipients receiving no 
psychotropic medication, followed by Whites at 40.30%.  The percentage of Black care 
recipients using one, two, and three psychotropic medications is higher than Whites and 
Hispanics. 
Between-Race Analysis 
 Logistic regressions analyses with each medication as an outcome and 
race/ethnicity as a predictor revealed that there were significant racial/ethnic disparities in 
the use of anxiolytics (Wald χ2=7.89, df=2, p=0.02), with Black care recipients having 
significantly higher risk of anxiolytic use relative to White care recipients (OR=1.84, 
p<0.01).  Significant racial/ethnic disparities were also observed for antipsychotics (Wald 
χ2=5.85, df=2, p=0.05) with Hispanics having significantly lower risk of antipsychotic 
use versus Whites (OR=0.57, p=0.05).  No significant racial/ethnic disparities in 
antidepressant use were observed, thus, no further investigation of between-race 
differences in antidepressant medication was performed. 
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 The results of the AIC model selection process for anxiolytics and antipsychotics 
are presented in Tables 4.3 and 4.4 respectively.  For both anxiolytics and antipsychotics, 
the top ten models contained approximately 90% of the total model weight, indicating 
that there was little need to examine combinations of variable sets contained in the lower-
ranked models.  Table 4.3 displays the AIC information for the top ten models predicting 
anxiolytics in direct comparison to the equivalent model with or without race.  The model 
containing race alone and the model containing race with all sets of predictors are also 
shown for reference.  Models are numbered by rank, with 1 being the most parsimonious.  
Recall that if a model without race is more parsimonious than the equivalent model 
containing race, racial/ethnic disparities in psychotropic medication can be explained by 
other variables in the model.  Here, Model 1 accounts for over half of the model weight 
and contains care recipient race/ethnicity, in addition to the sets of variables representing 
perceptions of caregiving, and caregiver socioeconomic status.  It is also worth noting 
that with the exception of Models 4 and 10, the top 10 models predicting anxiolytic 
medication contain race/ethnicity.  This provides strong support for the importance of 
race/ethnicity in addition to other variables sets that predict medication use. 
The evidence ratio comparing Model 1 to the same model without race/ethnicity 
(Model 4) is 14.38, indicating that, in repeated, independent samples from the population, 
Model 1 would be 14.38 times more likely to be selected as the best model versus the 
equivalent model without race.  Thus, there is strong support for the inclusion of race in 
addition to perceptions of caregiving and socioeconomic status.  It is also important to 
note that the model containing only race is ranked twenty-first and has a ΔAIC of 11.32.  
This provides overwhelming evidence that race is an important predictor of care recipient 
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anxiolytic use cannot be adequately represented by caregiver and care recipient variables 
alone.   
 In the same way that the importance of race/ethnicity in anxiolytic medication use 
was evaluated, we can also examine the importance of other variables sets.  For example, 
the difference between the top two models predicting anxiolytic use is the presence of 
socioeconomic status in Model 1.  The evidence ratio comparing Model 1 to Model 2 is 
6.00, indicating that there is considerably more support for the model containing 
socioeconomic status.  Comparing Model 1 to a similar model without perceptions of 
caregiving (Model 6) shows substantially more support for the larger, AIC minimal 
model (evidence ratio 22.87).   
 Table 4.4 displays the AIC information for the top 10 models predicting 
antipsychotic medication in direct comparison to the equivalent model without race.  
Model 1, the AIC optimal model accounts for over half of the total model weight and 
includes race/ethnicity, study site, and care recipient characteristics.  The equivalent 
model without race is ranked second with an evidence ratio of 3.01, indicating that there 
is approximately three times more evidence for the model containing race.  This is much 
weaker evidence for the role of race/ethnicity than was observed for anxiolytics, and 
suggests that caregiver attributes may better explain racial/ethnic disparities in care 
recipient’s use of anxiolytics versus antipsychotics.  
Another notable difference between anxiolytic and antipsychotic medication is 
that study site appears in each of the top ten models for antipsychotic use.  This indicates 
that there is substantial geographic variation across site that predicts antipsychotic 
medication.  In fact, the evidence ratio comparing Model 1 to an equivalent model 
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without site (Model 26) is 462.89.  Therefore, we have exceptionally strong evidence for 
the role of study site in predicting psychotropic medication use in this sample of 
community-dwelling dementia patients.   
Within-Race Analysis 
 Anxiolytic medications were used by 28 White/Caucasian care recipients 
(14.14%), 41 Black/African American care recipients (23.30%), and 22 of 
Hispanic/Latino care recipients (13.02%).  Among care recipients using an anxiolytic 
medication, 21.49% of White/Caucasians, 21.95% of Black/African Americans, and 
13.64% of Hispanic/Latinos had concomitant antipsychotic use.  Concomitant 
antidepressant use among anxiolytic users was observed in 17.85% of White/Caucasians, 
26.83% of Black/African Americans, and 31.82% of Hispanic/Latinos.  
 Antipsychotics were used by 64 White/Caucasian care recipients (32.23%), 46 
Black/African American care recipients (26.14%), and 36 Hispanic/Latino care recipients 
(21.30%).  Among care recipients using an antipsychotic medication, 9.38% of 
White/Caucasians, 19.57% of Black/African Americans, and 8.33% of Hispanic/Latinos 
were also taking an antipsychotic.  Concomitant antidepressant medication use was 
observed in 39.06% of White/Caucasian care recipients, 26.09% of Black African 
American care recipients, and 30.56% of Hispanic/Latino care recipients. 
 Antidepressants were used by 76 White/Caucasian care recipients (38.38%), 70 
Black/African American care recipients (39.77%), and 53 Hispanic/Latino care recipients 
(31.36%).  Among care recipients using antidepressant medications, 6.5% of   
White/Caucasians, 15.71% of Black/African Americans, and 13.21% of Hispanic/Latinos 
were also using an anxiolytic.  Concomitant antipsychotic use was observed in 32.89% of 
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White/Caucasian care recipients, 17.14% of Black/African American care recipients, and 
20.75% of Hispanic/Latino care recipients.  All three psychotropic medications were used 
by 7 White/Caucasian care recipients (3.53%), 7 Black/African American care recipients 
(3.98%), and 1 Hispanic/Latino care recipient (0.59%). 
 Tables 4.5 through 4.7 display the results for the multivariable within-race 
analyses for Whites, Blacks, and Hispanics respectively. As shown in Table 4.5, there 
were significant differences in anxiolytic and antidepressant medication use by study site 
for White/Caucasian care recipients. Being a non-spousal caregiver was associated with 
an approximately 40% increased risk of anxiolytic medication; however, the results were 
not statistically significant (OR=1.40, p=0.63).  As expected, increases in the frequency 
of problem behaviors and more behavioral bother was associated with an increased risk 
of medication (OR=1.02, p=0.30; OR=1.13, p=0.72 respectively), while perceiving more 
positive aspects of caregiving was protective (OR=0.97, p=0.28); however, these results 
did not achieve statistical significance.  
Poor self-reported health measures were associated with an approximate 40% 
increase in antipsychotics and antidepressants by White/Caucasian care recipients 
(OR=1.41, p=0.09; OR=1.41, p=0.04); however, the results for antipsychotics were not 
statistically significantly associated with self-reported health. Increases in positive 
perceptions of caregiving and care recipient age were significantly associated with a 
decreased risk of antidepressant use (OR=0.97, 0.05; OR=0.97, p=0.04 respectively). 
Final multivariable model results for psychotropic medication used by 
Black/African American care recipients are shown in Table 4.6.  Although not 
statistically significant, increased difficulty paying for basics was associated with a 
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decrease in the use of both anxiolytics and antipsychotics (OR=0.70, p=0.08, OR=0.85, 
p=0.40).  Increased confidence managing problem behaviors was associated with a 
decreased use of anxiolytics (OR=0.71 p=0.12) whereas increases in caregiving burden 
demonstrated a slight, positive association with medication use (OR=1.04, p=0.20); 
however, the estimates were not statistically significant. 
Statistically significant associations were not observed for predictors of 
antipsychotic medication in Black/African American care recipients; however, the 
directions of observed associations between care recipient and caregiver characteristics 
and antipsychotic medication are as expected.  For example, each additional functional 
impairment increased the risk of antipsychotic medication use by 4% (OR=1.04, p=0.64).  
Greater bother associated with providing assistance for functional impairments also 
increased the risk of antipsychotic medication use (OR=1.24, p=0.42). 
Statically significant associations were observed for antidepressant use in 
Black/African American care recipients.  Care recipient age was associated with a 
decreased risk of medication, which each additional year associated with a 5% reduction 
in antidepressant use (OR=0.95, p=0.02).  The caregiver’s use of spiritual and religious 
coping mechanisms also reduced the use of antidepressants by the care recipient 
(OR=0.91, p=0.05). 
Table 4.7 displays the results from the final multivariable models predicting 
psychotropic medication use by Hispanic/Latino care recipients. As shown, no Hispanics 
were recruited at the Birmingham or Memphis study sites, and therefore analyses were 
limited to Philadelphia, Miami, and Palo Alto.  Being a non-spousal caregiver and having 
poor self-reported health were the largest risk factors for care recipient anxiolytic use, 
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although the estimates were not statistically significant (OR=1.18 ,p=0.81; OR=1.44, 
p=0.12 respectively).  Larger caregiver social networks decreased the risk of anxiolytic 
use, with each additional member decreasing the risk of care recipient anxiolytic use by 
18% (OR=0.82, p=0.04). 
The results for the Latino/Hispanic antipsychotic analysis are also presented in 
Table 4.7.  In this analysis, study site was the strongest predictor of medication.  The risk 
of antipsychotic medication was also increased by care recipient pain.  Care recipients 
using a pain medication were 3.59 times more likely to also be using an antipsychotic 
compared to care recipients who were not receiving pain medication (OR=3.59, p=0.03).  
Finally, increasing caregiver satisfaction with social interactions was associated with 
more care recipient antipsychotic medication use (OR=1.20, p=0.02). 
Finally, both caregiver and care recipient characteristics were significantly 
associated with antidepressant medication use in Hispanic/Latino care recipients.  Higher 
levels of caregiver education and more negative social interactions were associated with 
decreases in antidepressants (OR=0.89 p=0.03; OR=0.84, p=0.02).  Better care recipient 
cognitive functioning increased the risk of medication use (OR=1.08, p=0.01). 
4.4 Discussion 
This study utilized a diverse sample of community dwelling-dementia patients 
and their care recipients to examine racial/ethnic patterns of psychotropic medication use 
among demented adults living outside of formal care facilities.  Comparing the 
prevalence of medication between care recipients from three different racial/ethnic 
groups, we observed significant disparities in the use of anxiolytic and antipsychotic 
medication use.  To examine reasons for the observed disparities, we used AIC model 
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selection techniques to determine whether models containing some combinations of 
variable sets representing care recipient characteristics, caregiver socioeconomic status, 
caregiver perceptions of caregiving, caregiver health, and non-financial caregiving 
resources were more parsimonious than the equivalent model containing race, thus 
implying that racial/ethnic disparities in psychotropic medication can be explained by 
these other factors We also stratified by race/ethnic group to examine predictors of 
psychotropic medication within Whites, Blacks, and Hispanics, and found that aspects of 
caregiver social networks influence psychotropic medication in Hispanic/Latino care 
recipients but not in other racial/ethnic groups. 
Contrary to study hypotheses, Black/African American Care recipients were almost 
twice as likely to use anxiolytic medication compared to White/ Caucasian care 
recipients.  These results are in contrast to published work from cross-sectional and 
longitudinal studies of the Established Populations for Epidemiologic Studies of the 
Elderly (EPESE) cohort.  Those works have consistently found higher rates of 
psychotropic medication use among community-dwelling, elderly Whites versus Blacks 
(19, 20, 59).  
Given that White and Black care recipients demonstrated similar levels of 
impairment and behavioral disorders in our study, one potential explanation for these 
disparate findings may be the time period in which the studies were conducted.  Data 
used in these studies were collected prior to the approval of rivastigmine, galantamine, 
and memantine (60).  Limited choice of FDA approved medications to manage dementia 
would likely increase the off label use of psychotropic medication for dementia 
symptoms during the time period of the EPESE studies.  Additionally, minority dementia 
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patients tend to receive a diagnosis later in the disease process compared to Whites, and 
once diagnosed, are less likely to access available treatment, which may have resulted in 
a higher prevalence of anxiolytic use among Whites (61).  Data for REACH II, on the 
other hand, were collected during the release of three cholinesterase inhibitors and 
memantine, an NMDA receptor antagonist.  Research has demonstrated racial/ethnic 
disparities in the use of new prescription drugs, with non-Hispanic Whites receiving more 
novel medications than non-Hispanic Blacks (62).  Therefore, it is possible that the 
higher prevalence of anxiolytic use by Black/African American care recipients in this 
study is a result of White/Caucasian care recipients transitioning to newer, FDA approved 
medications. 
We also found that Hispanic/Latino care recipients were approximately 40% less 
likely to use an antipsychotic medication than White/Caucasian care recipients.  Previous 
studies of psychotropic medication use among community dwelling elderly did not detect 
a disparity in antipsychotic medication use (16, 18); however, our results are consistent 
with findings from studies of FDA approved anti-dementia medication (2, 3, 5) that 
found a higher prevalence of cholinesterase inhibitor use among White/Caucasian 
dementia patients versus Hispanic/Latinos.  The discrepancy between our study and the 
null results from previous work may be due to differences in the study samples.  The 
previous investigations of antipsychotics were performed in community-dwelling elders 
who may have been receiving antipsychotic medication for reasons unassociated with 
Alzheimer’s and dementia.  Those studies would not necessarily find a racial/ethnic 
disparity in antipsychotic medication if the disparity was strongest among elderly adults 
with dementia. 
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Results from the AIC model selection analyses revealed that racial/ethnic 
disparities in anxiolytic and antipsychotic medication use could not be adequately 
explained by caregiver and care recipient characteristics.  This finding is commensurate 
with studies of cholinesterase inhibitors and NMDA receptor antagonists that found 
persistent inequalities after controlling for disease symptoms and social factors.  For 
example, a recent study of dementia treatment among Medicare beneficiaries uncovered 
racial/ethnic disparities in medication use that could not be fully explained by 
demographic, economic, health status, access to health care, or health care utilization (5).  
Similarly, the racial/ethnic disparities observed by Hernandez et al. could not be 
accounted for by gender, age, education, marital status, clinical referral, severity, and 
racial composition of the community (2). 
The finding of persistent racial/ethnic inequalities in medication used to treat 
dementia appears to be robust across FDA approved and non-approved medications, 
suggesting that there are still important explanations that have not been considered.  One 
potential unexplored explanation is medication adherence.  In a recent study of U.S. 
veterans with hypertension and dementia, Black and Hispanic patients demonstrated 
lower adherence to anti-hypertensive and anti-dementia medications relative to White 
patients (4).  Another study of Medicaid patients found that after adjustment for income, 
Hispanics were more likely to avoid filling prescription due to cost, resulting in higher 
rates of cost-related non-adherence in Hispanic enrollees compared to Non-Hispanic 
enrollees (63).  Therefore, it is possible that the racial/ethnic disparities in medication use 
observed in our study result from differing rates of adherence between the racial/ethnic 
groups.  Participants in the REACH trials were asked to supply all currently used 
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medications, making it difficult to know whether absence of a medication represents non-
adherence.  Future studies investigating racial/ethnic disparities in psychotropic drug use 
among community-dwelling dementia patients should attempt to collect detailed 
information on prescribed medications, filled prescriptions, and medication routines in 
order to address issues of adherence.  It is important to note, however, that this 
information should be used to increase adherence to medications that are deemed 
appropriate at the discretion of the physician. 
Our investigation also examined the predictors of psychotropic medication 
separately for Whites, Blacks, and Hispanics.  Although no clear patterns of predictors 
emerged for White or Black care recipients, analyses revealed that among 
Hispanic/Latino care recipients, larger social networks decreased the risk of anxiolytics, 
greater satisfaction with social support increased the risk of antipsychotics, and negative 
interactions with the social network were protective for antidepressants. This observation 
is consistent with a rich body of literature that identifies a more prominent role of 
extended social networks in the caregiving experience of Hispanic/Latino caregivers 
relative to White/Caucasian caregivers (35, 64, 65).  It is important to acknowledge, 
however, that these extended networks do not necessarily provide more support than the 
networks of Non-Hispanic white caregivers, but rather serve as a key mediator between 
caregiving and health outcomes (25, 66).   
Although investigating the mechanisms though which caregiver social support 
influence psychotropic medication use in the care recipient is beyond the scope of this 
paper, one plausible explanation may be found in the structure of Hispanic/Latino 
caregiving networks.  Among this racial/ethnic group, medication is most often managed 
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by older caregivers (greater than 50 years of age); however, the average age of a 
Hispanic/Latino caregiver in the United States is approximately 42 years (67)  It is 
therefore possible that positive interactions between a younger caregiver and an older 
member of the social network will increase the risk of medication for the care recipient.  
Future epidemiologic studies of community-dwelling dementia patients should make a 
special effort to recruit Hispanic/Latino caregiver/care recipient dyads and should collect 
information on caregiver social networks to better understand the mechanisms linking 
caregiver social support to care recipient medication outcomes in this growing 
population. 
Our analysis also revealed pain as a significant predictor of antipsychotic 
medication use in Hispanic/Latino care recipients.  Although we are the first study to 
report an association between pain and antipsychotic medication in community-dwelling 
Hispanic/Latinos with dementia, these results are consistent with reports of a positive 
association between pain and psychotropic medication among the greater population of 
dementia patients residing in the community (68, 69).  It is possible that our findings 
reflect a practice of polypharmacy where narcotic-induced delirium is addressed with 
psychotropic medication (70); however it is also possible that, among Hispanics/Latinos, 
behavioral manifestations of pain are misinterpreted as dementia symptoms.  The former 
explanation is supported by evidence that pain in Hispanics/Latinos is often 
undocumented in medical records and is subsequently undertreated (71).  Refined 
analyses using self-reported pain when available or pain-related diagnoses are needed to 
unravel this issue. 
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 The findings presented here should be evaluated within the context of the 
following limitations.  First, the variable sets representing caregiver socioeconomic 
factors, care recipient characteristics, caregiver health, perceptions of caregiving, and 
non-financial resources were constructed using available data and subsequently, are not 
exhaustive.  No formal examination of the extent to which variables within a set cluster 
together was made; however, all variables were chosen based on face validity and are 
reasonably expected to represent an important component of the variable set. 
Another important limitation is that the AIC model selection method used to 
assess racial/ethnic disparities in psychotropic medication use depends on the models 
input by the user.  The identified AIC optimal model is not the best from the universe of 
all possible models, but rather the best model from the ones chosen by the investigator.  
We based our choice of models on conceptual frameworks presented in the literature that 
outline determinants of psychotropic medication use in dementia caregiving and also how 
racial/ethnic disparities in medication use may arise.  We chose to include only main 
effects models in our analysis because (1) a variable that explains racial/ethnic variations 
in medication use will not necessarily interact with race and (2) evaluating interactions 
between multiple variable sets would necessitate an extremely large number of 
interactions resulting in a prohibitively large number of models to evaluate.  AIC model 
selection is not a test; therefore, p-values were purposefully omitted from model selection 
results. 
Another limitation of this study concerns the construction of the racial/ethnic 
groups.  In order to obtain sufficient sample size for an analysis of Hispanic/Latino care 
recipients, we combined Hispanic/Latino caregivers from different cultural subgroups, 
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largely Cuban and Mexican Americans.  Despite speaking the same language, these 
people represent distinct cultural groups that may differ with respect to perceptions of 
caregiving and care recipient health outcomes (72).  Additionally, we were unable to 
account for acculturation of the caregiver or care recipient.  Previous research has shown 
differences in neuropsychological measures of cognition and caregiver perceptions of 
caregiving by levels of acculturation (73).  Future studies should attempt to differentiate 
between different cultural groups and include acculturation measures whenever possible. 
The lack of medication dose information available in REACH II is also a 
limitation of this study.  The risk of adverse drug reactions increases at higher levels of 
medication intake.  We were therefore limited in our ability to identify predictors of the 
riskiest treatment levels of psychotropic medication.  Lack of dose information also 
restricted the extent to which we were able to identify racial/ethnic disparities in 
psychotropic medication use, as racial/ethnic minorities tend to receive higher doses of 
inappropriate medication (74). 
 REACH II data were collected before the release of the first FDA black box 
warning on the increased risk of death associated with antipsychotics in the elderly.  
Therefore, current dementia treatment patterns may differ from those observed here.  
Although we cannot specifically address this issues, a 2010 study by Dorsey et al. found 
that even after the release of the warnings, atypicals remained the most popular class of 
therapeutics among dementia patients, ranking second only to acetylcholinesterase 
inhibitors in each year of the study, suggesting that understanding the predictors of 
antipsychotic drug use in community-dwelling dementia patients is still a timely and 
important area of gerontological research (75).  Unfortunately, results were reported 
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irrespective of race. An interesting area of future research would be to investigate 
whether the racial/ethnic disparities in psychotropic medication use observed here 
persisted after release of the black box warnings.  Finally, it is important to note that 
REACH II was a randomized clinical trial and included individuals who were willing to 
participate in an intervention study.  These people may not be representative of all 
community-dwelling dementia patients and their caregivers. 
This study establishes a point of reference for evaluating racial and ethnic 
disparities in psychotropic medication use among dementia patients living in the 
community.  To our knowledge, this is the first study to examine predictors of 
psychotropic medication among demented racial and ethnic minorities living outside of 
formal care facilities, and as a result, is the first study to identify the importance of 
Hispanic/Latino caregiver social networks in care recipient psychotropic medication use.   
Additionally, our results highlight the need for better pain management strategies 
specifically among Latino community-dwelling elderly with dementia. 
 In conclusion, this study suggests that there are racial/ethnic disparities in the use 
of psychotropic medication by community-dwelling dementia patients and that social 
networks play a key role in Latino/Hispanic care recipient medication use.  These 
findings suggest that for Hispanics/Latinos, interventions aimed at improving 
communication between family members and other members of the social network may 
change care recipient medication use, although the extent to which psychotropics are 
appropriate is left to the discretion of the physician.  This work also provides valuable 
information to clinicians about the association between pain and psychotropic medication 
use.  More diligent evaluation and treatment of pain symptoms among Hispanic/Latino 
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dementia patients may be a reasonable strategy for reducing antipsychotic medication and 
improving patient quality of life.  
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4.5 Supplemental Equations 
The following equation is a mathematical representation of the general linear 
models used to assess study hypotheses (76).   
݈݋݃݅ݐ ሺߨ௜ሻ ൌ  ߙ ൅ ߚݔ௜+ ei 
Where ߨ௜ is the probability of medication for the ith care recipient.  The errors, ei 
are assumed to follow a normal distribution ~ܰሺ0, ߪଶሻ.  
The tools used to compare the ith model to the AIC minimal (AICmin) model in 
Tables 4.4 and 4.5 can be calculated with the following formulas (58). 
∆௜ൌ ܣܫܥ௜ െ ܣܫܥ௠௜௡ 
ܹ݄݁݅݃ݐ௜ ൌ ݁ݔ݌
ି∆೔ଶ
∑ ݁ݔ݌ି∆ೝଶோ௥ୀଵ
 
Where i=1,2,3,….R. 
ܧݒ݅݀݁݊ܿ݁ ݎܽݐ݅݋ሺ஺ூ஼೘೔೙,௜ሻ ൌ ௐ௘௜௚௛௧ಲ಺಴ ೘೔೙ௐ௘௜௚௛௧೔   
  
 
118
Table 4.1 Demographic Characteristics of Study Participants* 
 White/Caucasian Black/African American Hispanic/Latino 
Demographics Caregiver Care recipient Caregiver Care recipient Caregiver Care recipient 
  Age, years† 59.98 (12.68) 77.84 (10.26) 62.28 (12.82) 79.78 (8.41) 58.79 (14.12) 79.80 (8.98) 
  Sex, n (%)†       
    Female 161 (81.31) 101 (51.01) 149 (84.66) 110 (62.50) 136 (80.47) 113 (66.86) 
    Male 37 (18.69) 97 (48.99) 27 (15.34) 66 (37.50) 33 (19.53) 56 (33.14) 
  Employment  
  Status, n (%)§ 
      
    Unemployed 19 (9.60) - 20 (11.36) - 20 (11.83) - 
    Retired 92 (46.46) - 64 (36.36) - 51 (30.18) - 
    Homemaker 32 (16.16) - 30 (17.05) - 41 (24.26) - 
    Employed 55 (27.78) - 62 (35.43) - 57 (33.73) - 
  Years of Education§ 13.78 (1.96) - 13.05 (2.14) - 11.04 (3.95) - 
  Household Income§ 46,161.15 
(25,026.24) 
- 31,718 
(22,382.91) 
- 25,783.54 
(21,750.45) 
- 
  Income Adequacy 1.72 (1.02) - 1.66 (1.06) - 1.47 (1.00) - 
  Relationship to  
  care recipient, n(%)§ 
      
    Spouse 111 (56.06) - 52 (29.55) - 62 (36.69) - 
    Non-spouse 87 (43.94) - 124 (70.45) - 107 (63.31) - 
  Years caring for  
  care recipient 
3.98 (5.54) - 3.99 (3.96) - 6.22 (9.34) - 
* All values are presented as means and standard deviations, except where otherwise noted 
†p≤0.05 for chi-square test of homogeneity for care recipient variable 
§ p≤0.05 for chi-square test of homogeneity (discrete variable) or ANOVA (continuous variable) for caregiver variable  
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Table 4.2 Descriptive Statistics for Study Predictors and Outcomes 
  White/Caucasian Black/African American Hispanic/Latino 
Study Predictors and Outcomes Range* Mean (SD) Mean (SD) Mean (SD) 
Care recipient attributes      
  Cognitive status 0-30 11.61 (7.38) 12.62 (7.68) 12.78 (6.92) 
  Functional impairment 0-14 10.43 (2.80) 10.39 (2.84) 9.63 (3.39) 
  Number of problem  
  behaviors endorsed 
0-24 10.56 (4.11) 10.70 (4.04) 10.67 (3.83) 
  Pain, n (%) - 22 (11.11) 30 (17.05) 17 (10.06) 
Caregiver attributes     
  Self-reported health     
    Overall current health 0-4 2.10 (1.01) 2.06 (1.05) 2.24 (1.08) 
    Overall current health  
    compared to 6 months  
    previous 
0-4 2.06 (0.81) 2.10 (0.91) 2.27 (0.84) 
  Caregiver depression 0-60 9.58 (6.35) 9.66 (6.41) 10.75 (6.58) 
  Caregiver burden 0-48 16.88 (8.67) 17.03 (8.73) 17.81 (9.11) 
  Daily care bother 0-4 0.73 (0.76) 0.81 (0.83) 0.76 (0.77) 
  Problem behavior bother 0-4 1.42 (0.89) 1.56 (0.93) 1.44 (0.88) 
  Problem behavior confidence 0-4 2.19 (0.90) 2.04 (0.93) 1.91 (0.93) 
  Mastery 0-6 5.93 (2.70) 6.32 (2.96) 5.65 (2.94) 
  Vigilance 0-24 18.86 (6.70) 19.82 (6.24) 19.33 (6.95) 
  Positive aspects of  
  caregiving 
0-36 24.74 (8.93) 26.09 (8.82) 26.08 (8.70) 
  Spiritual and religious  
  coping 
0-18 15.22 (3.20) 15.13 (3.39) 13.95 (3.81) 
  Social Network     
    Social network size 0-10 6.70 (2.31) 6.63 (2.28) 5.90 (2.29) 
    Social support satisfaction 0-9 5.31 (2.58) 5.51 (2.86) 4.17 (2.82) 
    Negative social interaction 0-12 2.71 (2.57) 2.93 (3.03) 3.07 (2.78) 
  Dementia knowledge 0-4 2.93 (1.30) 2.24 (1.26) 1.90 (1.35) 
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Table 4.2 continued                                   
    White/Caucasian Black/African American Hispanic/Latino 
Study Predictors and Outcomes Range Mean (SD) Mean (SD) Mean (SD) 
Outcomes, n (%)      
  Anxiolytics† - 28 (13.93) 41 (23.30) 22 (12.94) 
  Antipsychotics† - 65 (32.34) 46 (26.14) 36 (21.18) 
  Antidepressants - 77 (38.31) 73 (39.77) 54 (31.76) 
*Indicates range of the measurement instrument 
†p≤0.05 for chi-square test of homogeneity 
§ p≤0.05 for ANOVA   
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Table 4.3 AIC Model Fit Information for Models Predicting Care Recipient Anxiolytic Use 
 Variable Set Included in the Model*      
Model 
Rank 
Care Recipient 
Race/Ethnicity 
Site A B C D E AIC ΔAIC Weight Rank of 
Equivalent 
Model Without 
Race  
Evidence 
Ratio† 
1 1 0 0 0 1 0 1 477.85 0.00 0.58 4 14.38 
2 1 0 0 0 1 0 0 481.83 3.98 0.08 10 6.00 
3 1 0 0 1 1 0 1 483.16 5.31 0.04 21 16.97 
:             
5 1 0 1 0 1 0 1 483.32 5.47 0.04 17 8.02 
6 1 0 0 0 0 0 1 483.83 5.98 0.03 35 22.87 
7 1 0 0 0 1 1 1 483.99 6.14 0.03 22 11.78 
8 1 0 0 1 0 0 1 484.26 6.41 0.02 42 25.85 
9 1 1 0 0 1 0 1 484.58 6.73 0.02 40 20.79 
:             
21 1 0 0 0 0 0 0 489.32 11.32 <0.01 NA NA 
:             
110 1 1 1 1 1 1 1 499.74 21.89 <0.01 125 11.95 
*Inclusion in the model is indicated by 1, exclusion is indicated by 0 
  Set A includes care recipient variables (cognitive impairment, functional impairment, problem behavior frequency, pain, relationship  
  to the caregiver, sex, and age 
  Set B includes caregiver health variables (self reported health both current and current compared to six months previous, and  
  depression) 
  Set C includes perceptions of caregiving (caregiving burden, bother assisting with functional impairments, bother handling problem  
  behaviors, confidence handling problem behaviors, caregiving mastery, vigilance, and positive aspects of caregiving)  
  Set D includes non-financial caregiving resources (spiritual and religious coping, social network size, social network     
  satisfaction, negative social interaction, and dementia knowledge 
  Set E includes caregiver socioeconomic status (education, employment, income, and income adequacy) 
†Evidence ratio comparing model with race to an equivalent model without race  
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Table 4.4 AIC Model Fit Information for Models Predicting Care Recipient Antipsychotic Use 
 Variable Set Included in the Model*      
Model 
Rank 
Care Recipient 
Race/Ethnicity 
Site A B C D E AIC ΔAIC Weight Rank of 
Equivalent 
Model With or 
Without Race 
Evidence 
Ratio† 
1 1 1 1 0 0 0 0 616.26 0.00 0.51 2 3.03 
:             
3 1 1 1 1 0 0 0 619.29 3.03 0.11 4 3.88 
:             
5 1 1 0 0 0 0 0 622.49 6.23 0.02 15 3.85 
6 1 1 1 0 0 1 0 622.94 6.69 0.02 12 1.78 
:             
9 1 1 1 0 1 0 0 623.35 7.09 0.01 16 2.59 
10 1 1 1 0 0 0 1 623.88 7.62 0.01 7 0.65 
:             
41 1 1 1 0 1 0 1 630.91 14.65 <0.01 8 0.02 
:             
50 1 0 0 0 0 0 0 632.21 16.21 <0.01 NA NA 
:             
82 1 1 1 1 1 1 1 636.41 20.16 <0.01 67 0.33 
*Inclusion in the model is indicated by 1, exclusion is indicated by 0 
  Set A includes care recipient variables (cognitive impairment, functional impairment, problem behavior frequency, pain, relationship  
  to the caregiver, sex, and age 
  Set B includes caregiver health variables (self reported health both current and current compared to six months previous, and  
  depression) 
  Set C includes perceptions of caregiving (caregiving burden, bother assisting with functional impairments, bother handling problem  
  behaviors, confidence handling problem behaviors, caregiving mastery, vigilance, and positive aspects of caregiving)  
  Set D includes non-financial caregiving resources (spiritual and religious coping, social network size, social network     
  satisfaction, negative social interaction, and dementia knowledge 
  Set E includes caregiver socioeconomic status (education, employment, income, and income adequacy)  
†Evidence ratio comparing model with race to an equivalent model without race  
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Table 4.5 Predictors of Psychotropic Medication for White/Caucasian Care 
Recipients 
Variable Anxiolytics Antipsychotics Antidepressants 
 Odds 
ratio 
95% CI Odds 
ratio 
95% CI Odds 
ratio 
95% CI 
Site       
  Philadelphia REF - REF - REF - 
  Birmingham 2.42 (0.44, 13.19) 1.35 (0.54, 3.39) 2.63 (1.01, 6.82) †
  Memphis 1.25 (0.20, 7.66) 0.64 (0.24, 1.67) 0.67 (0.24, 1.84) 
  Miami 6.44 (1.17, 35.40)† 1.52 (0.51, 4.53) 1.13 (0.36, 3.53) 
  Palo Alto 2.65 (0.45, 15.61) 0.48 (0.15, 1.48) 0.87 (0.29, 2.61) 
Care recipient attributes       
  Sex       
   Female REF - REF - REF - 
   Male 2.86 (0.70, 11.71) 0.54 (0.23,1.25) 1.28 (0.54, 3.06) 
  Age at baseline 1.00 (0.95, 1.05) 0.99 (0.96, 1.02) 0.97 (0.94, 0.99) † 
  Functional  
  impairment 
  1.12 (0.98, 1.26) 
  Problem behavior   
  frequency 
1.02 (0.98, 1.07)     
Caregiver attributes       
  Education 1.08    (0.85, 1.37) 1.10     (0.93, 1.31) 0.99 (0.84, 1.17) 
  Income adequacy       
  Relationship to care  
  Recipient 
      
   Spouse REF - REF - REF - 
   Non-Spouse 1.38 (0.35, 5.47) 0.64 (0.28, 1.47) 1.04 (0.45, 2.41) 
  Self-reported health       
   Overall current  
    health 
    1.41 (1.02, 1.96)† 
   Overall current  
   health compared to    
   6 months previous 
  1.41 
 
(0.94, 2.09)   
   Caregiver depression 1.05 (0.97, 1.14)     
  Caregiver burden 1.01 (0.93, 1.09)     
  Problem behavior      
  bother 
1.13 (0.58, 2.23)     
  Positive aspects of  
  caregiving 
0.97 (0.91, 1.02)   0.97 (0.93, 0.99)† 
*Estimates from logistic regression model controlling for site, care recipient sex, age at baseline, 
caregiver relationship to the care recipient, and income adequacy 
†p≤0.05 
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Table 4.6 Predictors of Psychotropic Medication for Black/African American Care 
Recipients 
Variable Anxiolytics Antipsychotics Antidepressants 
 Odds 
ratio 
95% CI Odds 
ratio 
95% CI Odds 
ratio 
95% CI 
Site       
  Philadelphia REF - REF - REF - 
  Birmingham 1.10 (0.32, 3.76) 1.45 (0.49, 4.29) 1.45 (0.52, 4.00) 
  Memphis 1.91 (0.35, 4.09) 0.43 (0.13, 1.14) 2.05 (0.73, 5.74) 
  Miami 1.20 (0.31, 4.66) 0.73 (0.20, 2.65) 0.53 (0.15, 1.84) 
  Palo Alto 0.34 (0.05, 2.16) 0.61 (0.12, 3.08) 1.04 (0.27, 3.97) 
Care recipient attributes       
  Sex       
   Female REF - REF - REF - 
   Male 0.79 (0.31, 2.03) 0.66 (0.26, 1.66) 1.05 (0.47, 2.33) 
  Age at baseline 1.00 (0.95, 1.05) 0.98 (0.93, 1.03) 0.95 (0.91, 0.99) †
  Cognitive status   0.95 (0.90, 1.00)    
  Functional impairment   1.04 (0.89, 1.22)   
  Problem behavior  
  frequency 
1.00    (0.96, 1.05)     
Caregiver attributes       
  Education 1.08 (0.89,1.31) 1.01 (0.83, 1.22) 1.01 (0.85, 1.19) 
  Income adequacy 0.70 (0.47, 1.04) 0.85 (0.59, 1.24)   
  Relationship to care  
  Recipient 
      
   Spouse REF - REF - REF - 
   Non-Spouse 0.65 (0.24, 1.80) 1.37 (0.50, 3.75) 1.19 (0.50, 2.82) 
  Self-reported health       
    Overall current 
    health 
1.41 (0.93, 2.16)     
    Caregiver depression 0.96 (0.88, 1.05) 1.01 (0.94, 1.09)   
  Caregiver burden 1.40 (0.98, 1.10) 1.01 (0.96, 1.08)   
  Functional  
  impairment bother 
  1.24 (0.73, 2.11)   
  Problem behavior  
  confidence 
0.71 (0.46, 1.10)     
  Vigilance 1.01 (1.00, 1.18) 1.07 (0.99, 1.15)   
  Spiritual and  
  religious coping 
    0.91 (0.82, 1.00) †
*Estimates from logistic regression model controlling for site, care recipient sex, age at baseline, 
caregiver relationship to the care recipient, and income adequacy 
†p≤0.05 
  
  
125 
 
Table 4.7 Predictors of Psychotropic Medication for Hispanic/Latino Care 
Recipients 
Variable Anxiolytics Antipsychotics Antidepressants 
 Odds 
ratio 
95% CI Odds 
ratio 
95% CI Odds 
ratio 
95% CI 
Site       
  Philadelphia REF - REF - REF - 
  Birmingham - - - - - - 
  Memphis - - - - - - 
  Miami 1.16 (0.27, 4.99) 9.27 (2.07, 41.48)† 1.51    (0.51, 4.44) 
  Palo Alto 0.83 (0.19, 3.59) 1.98     (0.42, 9.21) 0.98    (0.34, 2.83) 
Care recipient 
attributes 
      
  Sex       
   Female REF - REF - REF - 
   Male 1.45 (0.42, 5.02) 1.38     (0.43, 4.42) 1.43 (0.55, 3.72) 
  Age at baseline 0.97 (0.92, 1.03) 1.03     (0.97, 1.08) 0.98    (0.94, 1.02)  
  Cognitive status   0.97     (0.91, 1.04)  1.08    (1.02, 1.14)† 
  Functional  
  impairment 
 1.14     (0.98, 1.33)   
  Pain       
    No REF - REF - REF - 
    Yes 1.04 (0.21, 5.27) 3.59     (1.12, 11.52)† 2.48 (0.77, 7.97) 
Caregiver attributes       
  Education 1.00  (0.88, 1.15) 0.98 (0.87, 1.10) 0.89 (0.80, 0.99)† 
  Income adequacy     1.16 (0.79, 1.70) 
  Relationship to  
  care recipient 
      
   Spouse REF - REF - REF - 
   Non-Spouse 1.18 (0.31, 4.56) 1.79     (0.54, 5.93) 2.00    (0.70, 5.76) 
  Self-reported  
   health 
      
   Overall current  
   health 
1.44 (0.91, 2.27)     
  Problem behavior     
  bother 
  0.77     (0.48, 1.25) 1.46    (0.93, 2.28) 
  Positive aspects  
  of caregiving 
    0.98    (0.93, 1.02) 
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Table 4.7 continued 
Variable Anxiolytics Antipsychotics Antidepressants 
 Odds 
ratio 
95% CI Odds ratio 95% CI Odds 
ratio 
95% CI 
Social network       
  Social network  
  size 
0.82 (0.67, 0.99)†     
  Social support  
  satisfaction 
  1.20       (1.03, 1.41) †   
  Negative  
  interaction 
    0.83    (0.72, 0.98)† 
*Estimates from logistic regression model controlling for site, care recipient sex, age at baseline, 
caregiver relationship to the care recipient, and income adequacy 
†p≤0.05 
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Figure 4.1 Care Recipient Psychotropic Medication Prevalence by Race/Ethnicity 
 
 
 
 
Figure 4.2 Number of Care Recipient Psychotropic Medications by Race/Ethnicity 
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Chapter 5  
 
Conclusions 
Dementia is one of the most devastating and challenging diseases facing society 
today.  Although cognitive decline is often referred to as the hallmark symptom of 
dementia, behavioral and psychological symptoms are highly prevalent over the course of 
disease (1).  These symptoms are often unpredictable and complicate care, and are a 
legitimate focus for pharmacologic intervention; however, unlike cognitive dementia 
symptoms, there are currently no approved medications for the treatment of dementia-
related behavioral disturbances.  Psychotropic medications, antipsychotics in particular, 
have filled this niche without an approved dementia indication for over fifty years.  
Recent negative safety findings combined with reports of modest efficacy bring this 
practice into question suggesting that the potential benefits may be outweighed by the 
substantial risks (2). 
Most studies of psychotropic medication use in dementia patients have focused on 
patients residing in formal care facilities, with little attention paid to dementia patients 
residing in the community (3-6).  This dissertation adds to the current literature by 
investigating cross-sectional and longitudinal predictors of psychotropic medication use 
in racially and ethnically diverse populations of community-dwelling dementia patients 
and their caregivers.  Understanding the predictors of psychotropic medication use in 
community-dwelling dementia patients will help researchers develop interventions aimed 
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at reducing unsafe use of these medications and may potentially help guide health care 
policy, particularly related to clinical practice and education. 
5.1 Summary of findings 
Chapter 2 presents a cross-sectional study examining the predictors of 
psychotropic medication use, going beyond traditional behavioral risk factors and 
including caregiver perceptions of caregiving and care recipient pain in order to obtain a 
comprehensive understanding of the patterns of psychotropic medication use in 
community-dwelling elderly with dementia.  Using a racially diverse sample of 
Alzheimer’s patients and their informal caregivers, we found that the prevalence of care 
recipient psychotropic medication use among dementia patients living in the community 
was comparable to that observed in nursing homes (4), with over half of care recipients 
using at least one anxiolytic, antipsychotic, or antidepressant medication.   
Similar to studies of traditional risk factors, our findings revealed that more 
problematic behaviors were significantly associated with increased odds of anxiolytic 
medication (7, 8).  Importantly though, this association was only observed in bivariate 
analyses and did not remain when caregiver attributes were included in multivariable 
analyses.  Increases in caregiver confidence managing problem behaviors was 
statistically significantly associated with a decreased risk of anxiolytic medication use, 
suggesting that caregiver confidence may be an important target for interventions aimed 
at reducing the use of anxiolytic medication by elderly dementia patients living in the 
community. 
The other major finding of Chapter 2 was the strong association between care 
recipient pain and the use of antipsychotic medication.  Many times, dementia patients 
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are unable to verbally report pain, and as a result, act out in ways that can be 
misinterpreted as neurological symptoms of dementia (9, 10).  This research suggests that 
treatment of behavioral disturbances with antipsychotic medication may actually be 
misguided efforts at addressing pain. 
To our knowledge, this is the first study to investigate caregiver and care recipient 
characteristics of psychotropic medication use among demented adults living in the 
community.  The risk of serious adverse events associated with the use of these 
medications by patients with dementia emphasizes the importance of identifying 
potentially modifiable risk factors for medication use.  This study supports that effort by 
focusing on a relatively understudied group of dementia patients and expanding the 
current scope of potential risk factors to include care recipient pain and informal 
caregiver characteristics. 
The study presented in Chapter 3 extends the work presented in Chapter 2 by 
examining the longitudinal association between caregiver perceptions of caregiving, 
dementia patient symptoms, and the risk of care recipient psychotropic medication to 
determine whether the risk of medication changes over time as health declines and the 
risk of adverse drug events increase.  Prior to conducting this comprehensive analysis, we 
first evaluated whether caregiver participation in the REACH I six-month intervention 
designed to reduce caregiver burden and depression influenced psychotropic medication 
in the care recipient during the intervention period.  This preliminary analysis revealed 
that intervention was not associated with changes in care recipient psychotropic 
medication use. 
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Similar to the results in Chapter 2, our main analysis found that caregiver and care 
recipient characteristics are important predictors of care recipient psychotropic 
medication use.  Again, more problematic behaviors were significantly associated with 
increased odds of anxiolytic medication in bivariate analyses; however, the association 
was no longer significant when modeled together with caregiver attributes.  
Unfortunately, caregiver confidence managing problematic behaviors was not available 
in this dataset, making a direct comparison to results presented in Chapter 2 difficult.  
This study, however, found that caregiver bother managing problem behaviors was the 
strongest predictor of care recipient anxiolytic medication use.  Taken together with the 
results from Chapters 2, these findings suggest that caregiver efficacy and bother 
associated with problematic behaviors may be important targets for interventions aimed 
reducing anxiolytic use in community-dwelling elderly with dementia. 
Another important finding of this study was the varying association between care 
recipient functional impairment and antipsychotic use over time.  We found that care 
recipient functional impairment was associated with an increased risk of antipsychotic 
medication; however, the association was significantly attenuated over time. This finding 
may explain why previous investigations have failed to detect an association between 
functional impairment and antipsychotic medications (11) and suggests that strategies to 
reduce antipsychotic medication use in community-dwelling dementia patients may need 
to change over the course of disease. 
We believe that this is the first study to evaluate longitudinal predictors of 
psychotropic medication in community-dwelling dementia patients.  Although the 
REACH I caregiver intervention was not associated with changes in care recipient 
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medication use in this study, the work contained in Chapters 2 and 3 provides valuable 
information for the development of future interventions.  Specifically, our studies suggest 
that increasing caregiver efficacy and reducing bother associated with care recipient 
problem behaviors may be a reasonable strategy for decreasing anxiolytic drug use 
among community-dwelling dementia patients while also improving caregiver quality of 
life.  Furthermore, intervention strategies to reduce antipsychotic use will likely need to 
change over the course of disease to account for the fluctuation of medication risk factors 
over time.   
To accomplish this, we recommend that psychotropic minimization efforts focus 
on training caregivers to recognize the signs of frustration and negative thought patterns 
and teaching strategies for modifying negative thoughts.  Additionally efforts should be 
directed towards educating caregivers on dementia caregiving skills and helping them 
achieve mastery of the skills demanded by their caregiving situation.  This includes 
modeling caregiving behaviors; providing feedback and encouragement; and helping 
caregivers identify and solicit help.  These comprehensive strategies have been shown to 
increase efficacy and decrease bother associated with problem behaviors in spousal 
caregivers of dementia patients.  The improvement in caregiver appraisals was also 
observed to persist over time as treatments were sensitive to changes in caregiver needs 
as caregiving responsibilities transitioned from managing problem behaviors to assisting 
with functional impairments (12). 
The final study of this dissertation, presented in Chapter 4, examines patterns of 
psychotropic medication use both within and between community-dwelling dementia 
patients from three different racial/ethnic groups.  Given the documented racial/ethnic 
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disparities in FDA approved anti-dementia medications (13-16), we hypothesized that the 
prevalence of psychotropic medication would be higher in non-Hispanic Whites 
compared to Hispanics/Latinos or Black/African Americans.  In our study however, 
Black care recipients had a higher risk of anxiolytic medication use relative to Whites.  
This finding was in contrast to several previous works that found higher rates of 
psychotropic medication in non-Hispanic Whites versus non-Hispanic Blacks (17-19).  A 
potential explanation for this discrepancy may be the time period in which the data were 
collected.  The participants in this analysis were recruited during the release of three 
cholinesterase inhibitors and memantine, an NMDA receptor antagonist.  Therefore, the 
higher prevalence of anxiolytic use in Black/African Americans may be the result of 
White/Caucasian care recipients transitioning to newer, FDA approved medications more 
quickly than Black/African American care recipients FDA.  This hypothesis could be 
tested using data from the Medicare Current Beneficiary Survey (MCBS), a continuous 
sample of Medicare recipients conducted by the Centers for Medicare and Medicaid 
Services.  Participants in the MCBS are asked a battery of questions relating to 
demographics, health status, health care utilization, and insurance coverage.  Information 
from the MCBS can be linked to claims data containing diagnostic indicators, 
prescription fills, and payment information (16).  Using the MCBS, a retrospective cohort 
analysis of community-dwelling dementia patients could be undertaken to determine if 
the risk of anti-dementia medications associated with race/ethnicity changes over time.  
Time plots and interaction plots could be used to visually examine the trends of 
medication use over time by race and would provide evidence that Black/African 
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American dementia patients transitioned to FDA approved anti-dementia medications at a 
slower rate than White/Caucasian patients. 
In efforts to better understand the observed disparities in psychotropic medication 
use, we used AIC model selection methods to determine whether racial/ethnic disparities 
in psychotropic medication could be explained by sets of variables representing 
socioeconomic status, care recipient characteristics, caregiver perceptions of caregiving, 
caregiver health, and non-financial caregiving resources.  These analyses revealed that 
racial/ethnic disparities in psychotropic medication use could not be adequately explained 
by caregiver and care recipient characteristics.  This finding is commensurate with 
studies of cholinesterase inhibitors and NMDA receptor antagonists that found persistent 
inequalities after controlling for disease symptoms and social factors (13, 16), suggesting 
that observed disparities in medication use may be attributable to cultural attitudes 
towards health care and medication (20) or health care biases in prescribing treatment 
that is not commonly measured in studies of community-dwelling dementia patients and 
their caregivers.  Future studies should attempt to collect information on informal 
dementia caregiver attitudes towards health care and current dementia treatment options.  
Studies focusing on physicians, the most frequent prescribers of psychotropic medication 
(21) should also be conducted to identify opportunities for modifying biases that result 
potentially dangerous prescription patterns. 
The final goal of this study was to address the lack of published literature 
regarding the predictors of psychotropic medication within minority, community-
dwelling, dementia patients.  To that end, we examined predictors of psychotropic 
medication within White, Black, and Hispanic dementia patients.  Although no clear 
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pattern of predictors emerged for White or Black care recipients, aspects of social 
networks were significantly associated with the use of anxiolytics, antipsychotics and 
antidepressants within Hispanic/Latino care recipients.  These results are consistent with 
a rich body of literature that finds extended social networks to be particularly important 
to Hispanic/Latino caregivers relative to White/Caucasian caregivers (22, 23), but are the 
first to identify social networks as a determinant of dementia patient psychotropic 
medication use. 
5.2 Limitations and Strengths 
Some important limitations of this research need to be considered when 
evaluating the results presented herein.  First, all study hypotheses were evaluated using 
data obtained from REACH intervention participants and may not be generalizable to the 
population of dementia patients living in the community.  For example, eligible 
caregivers for the REACH trials needed to have provided care for at least six months and 
be the primary caregiver involved with daily care tasks and other caregiving 
responsibilities.  Additionally, it is reasonable to expect that interventions aimed reducing 
caregiver burden and improving caregiver quality of life would attract caregivers most in 
need of intervention services. These selection biases likely explain the relatively high 
levels of care recipient impairment and caregiver burden exhibited in the REACH data.  
Consequently, the associations observed in these studies may not apply to newer 
caregivers of patients with recently diagnosed disease.  The narrow selection of study 
participants and limited follow-up period may have also hindered our ability to detect 
changes in predictors of medication use over time.  As discussed in Chapter 3, enrolling 
patients at various stages of dementia and increasing follow-up time may have increased 
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our ability to detect changes in anxiolytic use and may have also revealed a more 
pronounced association between functional impairment and antipsychotics. 
Another limitation of this research concerns the lack of medication dosing 
information available in REACH.  The risk of adverse drug reactions increases at higher 
levels of medication intake.  We were therefore limited in our ability to identify 
predictors of the riskiest treatment levels of psychotropic medication.  Lack of dose 
information also restricted the extent to which we were able to identify racial/ethnic 
disparities in psychotropic medication use, as racial/ethnic minorities tend to receive 
higher doses of inappropriate medication (24).    
An additional limitation of the racial/ethnic disparities work presented in Chapter 
3 relates to the construction of the racial/ethnic groups.  This investigation combined 
Hispanic/Latino caregivers from different cultural subgroups.  A majority of the REACH 
Hispanic/Latino participants were Cuban and Mexican Americans.  Despite speaking the 
same language, these people represent distinct cultural groups that may differ with 
respect to perceptions of caregiving and care recipient health outcomes (25).  We were 
also unable to account for acculturation of the caregiver or care recipient.  Consequently, 
we may be missing an important predictor of psychotropic medication use as previous 
research has shown differences in neuropsychological measures of cognition and 
caregiver perceptions of caregiving by levels of acculturation (26). 
Lastly, REACH data were collected before the release of the first FDA black box 
warning on the increased risk of death associated with antipsychotics in the elderly.  
Therefore, current dementia treatment patterns may differ from those observed in our 
study.  As discussed in previous chapters; however, psychotropic medication, particularly 
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antipsychotics are still widely used in people with dementia (27), indicating  that 
understanding the predictors of psychotropic drug use in community-dwelling dementia 
patients is still a timely and important area of gerontological research. 
Nonetheless, this dissertation has many strengths, most notably, the rich data 
source used for each analysis.  The REACH studies were designed to assess caregiver 
interventions, and as a result, contain a reasonably large, diverse, sample that is well-
described from a caregiver perspective.  In addition to information about informal 
caregivers, REACH also collected information on community-based psychotropic 
medication use.  Using this unique data source allowed us to be the first investigators to 
examine caregiver and care recipient characteristics as predictors of psychotropic 
medication use in community-dwelling dementia patients both cross-sectionally, and over 
time.   
Another advantage of the REACH data is the inclusion of participants from three 
different racial/ethnic groups.  The large number of Whites, Blacks, and Hispanics 
allowed us to examine racial/ethnic disparities in psychotropic medication use and also 
enabled us to identify medication risk factors within each racial/ethnic group separately.  
This is an important improvement from previous research that tended to dichotomize race 
into White/Non-White categories (11). 
5.3 Future Research Directions 
The risks associated with psychotropic drug use in people with dementia are well-
established (2).  Antipsychotics in particular carry substantial risks including death, and 
consequently should only be used as a last resort, when all other attempts to manage 
symptoms have failed.  In order to have reasonable non-pharmacologic alternatives, it is 
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imperative to understand the context in which psychotropic medication is used.  A 
majority of the work examining psychotropic medication use in dementia patients focuses 
on the formal care setting, with very little attention paid to patients living in the 
community (3-6).  The conclusions drawn from nursing home populations cannot 
necessarily be applied to community-dwelling dementia patients, however, as these 
individuals tend to be healthier and less functionally impaired than people who are 
institutionalized.  Additionally, dementia patients in the community generally receive 
care from informal caregivers who are balancing other responsibilities while providing 
round-the-clock assistance (28).  Future studies of community-dwelling dementia patients 
and their caregivers should be longitudinal, enrolling participants at the earliest possible 
stages of disease to provide information on patterns of symptoms, caregiver perceptions 
and treatment patterns over time.  Future work should also consider using instruments 
such and the Neuropsychiatric Inventory (29) to identify the problem behaviors that are 
most troubling to caregivers and consequently likely to result in psychotropic medication.  
Interventions could then focus on helping caregivers manage the identified disturbances 
and the emotional distress that accompanies them.  Along similar lines, studies should 
also examine caregiver reactions to resistance to care, as it has been identified as a 
predictor of caregiver stress and therefore may be an important risk factor for 
psychotropic medication (30). 
In order for research to move forward, appropriate data sources will need to be 
developed.  Currently, there is a dearth of information available on community-dwelling 
dementia patients, their medications, and informal caregivers.  In fact, one of the largest 
strengths of this dissertation is the ability to examine caregivers and care recipients 
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together.  We recommend that future efforts focus on gathering detailed dementia patient 
information in addition to objective and subjective caregiver information, either through 
the creation of new study cohorts, or through the expansion of existing aging cohorts.  
These cohorts will be essential for understanding the extent to which psychotropic 
medications are used in community-dwelling dementia patients and the reasons for their 
use. 
Another recommendation for future research concerns the assessment of risk 
associated with antipsychotic use in dementia patients.  A recent meta-analysis of 
placebo-controlled trials of antipsychotics in dementia patients released in September 
2011 by the Agency for Health Care Research and Quality (AHRQ) found small but 
statistically significant reductions in problematic behaviors associated with use of 
aripiprazole, olanzapine, and risperidone (2).  These results indicate that despite the risk 
of significant harm, some dementia patients do benefit from antipsychotic use and that 
there are subgroups of dementia patients where treatment with antipsychotics may be 
particularly valuable.  Unfortunately, the FDA’s antipsychotic black box warning is a 
blanket warning for all antipsychotics and does not provide information about which 
antipsychotic poses the greatest risk (31-33).  Furthermore, there is little information 
available regarding risk factors for increased mortality in elderly users of antipsychotics.  
This lack of information is unacceptable given that there are currently no other treatment 
options available for managing behavioral disturbances in dementia.  We recommend that 
future research evaluate atypical antipsychotic drugs with respect to their risk of serious 
cardiovascular events and mortality in elderly dementia patients.  We also recommend 
that research efforts be directed towards finding risk factors that will identify patients at 
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the greatest risk for a serious adverse event.  This detailed risk information is essential for 
protecting community-dwelling dementia patients, as they are not protected by the federal 
regulations that guide antipsychotic prescribing in nursing homes. 
Finally, building upon the previous suggestions above, we recommend that 
researchers make a special effort to recruit community-dwelling, minority dementia 
patients into research on psychotropic medication use.  Racial/ethnic minorities are the 
fastest growing group of dementia patients in the United States (34, 35) and are more 
likely to remain in the community relative to White/Caucasian patients (23, 36).  
Additionally, previous research has demonstrated racial/ethnic variation in several 
variables that may influence psychotropic medication use including dementia knowledge, 
concerns about dementia, and beliefs about effectiveness of treatment (20).  
Consequently, a “one size fits all” non-pharmacologic treatment alternative will likely 
fail at reducing medication use in minority populations.  Understanding the predictors of 
psychotropic medication within diverse groups of community-dwelling patients will be 
essential for designing culturally-relevant interventions that reduce psychotropic 
medication among minority dementia patients living in the community. 
Racial and ethnic variation in drug response has also been well-described in the 
literature (37, 38).  Although the reasons behind racial heterogeneity of treatment 
response are not fully understood, they are thought to reflect fundamental differences in 
the pathogenesis of disease, environment, and distributions of polymorphisms in drug 
receptors or drug-metabolizing enzymes across racial/ethnic groups (39). Future research 
of psychotropic medication use in dementia patients should include a diverse group of 
community-dwelling dementia patients, as race/ethnicity may be a risk factor for adverse 
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cardiovascular events or death.  This information will not only help protect the most 
vulnerable community-dwelling dementia patients, but will also provide context for 
observed racial/ethnic disparities in medication use. 
5.4 Public Health Policy Implications 
The research presented in this dissertation also has important implications for 
public health policy in terms of demonstrating a need for public health action and 
recommendations for the type of action that needs to occur. We found that the prevalence 
of psychotropic medication use among community-dwelling dementia patients was quite 
high and similar to reports of psychotropic medication use in nursing home residents (4), 
suggesting that the current health system delivers a largely pharmaceutical based 
response to managing behavioral disturbances in community-dwelling adults with 
dementia. This is in direct opposition to the American Academy of Neurology Practice 
Parameters that support psychotropic intervention only as a second line response after 
non-pharmaceutical interventions have failed (40).  The substantial risks associated with 
psychotropic medications in combination with the high levels of use in community-
dwelling dementia patients are a blatant indication that current health and social systems 
have failed to provide an appropriate response to dementia care.  Based on a review of 
common dementia treatment practices and our findings of the importance of an informal 
dementia caregiver in predicting psychotropic medication use, we offer the following 
practical recommendations for policy changes that will improve dementia care for 
patients residing in the community. 
In the United States, most dementia patient psychotropic medication prescriptions 
are dispensed by primary care physicians without consultation from a specialist, 
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geriatrician, gerontological clinical nurse specialist, or nurse practitioner (21).  It is 
therefore reasonable to expect that future efforts at reducing psychotropic medication use 
in dementia patients will need to include changes to the way general practitioners assess 
and treat individuals with dementia.  At the very least, state medical boards should 
develop a curriculum for physician education around the management of dementia-
related behavioral disturbances and the availability of local social assistance services.  
This training should be available as continuing medical education.   
Although focusing on physician education and physician interactions with 
patients will address one deficiency of the current health care system and may help 
eliminate racial/ethnic disparities in medication use, it will likely be insufficient for 
reducing psychotropic medication use in community-dwelling dementia patients when 
used in isolation.  Our research indicates that perceptions of informal caregivers will also 
need to be addressed.  This point is supported by a 2007 report by Hinton et al. that 
examined the challenges physicians face in managing dementia-related behavioral 
disturbances.  Dementia caregivers often arrive at office visits with intense social and 
psychological needs that general practitioners are not able to directly address.  As a 
result, doctors may prescribe psychotropics as a way to alleviate caregiver stress 
associated with managing screaming and hallucinations (41).  Although there is evidence 
that antipsychotics may provide small reductions in dementia-related behavioral 
disturbances (2), using psychotropic medication as a general strategy to reduce caregiver 
distress is inappropriate-- nonpharaceutical interventions have been shown to effectively 
reduce caregiver bother and increase caregiver efficacy (12). 
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Instead, a comprehensive approach to dementia care that involves both dementia 
patients and informal caregivers is needed.  The focus for dementia treatment needs to be 
directed away from primary care physicians to a multidisciplinary team including 
physicians and nurses with special training in gerontology, counselors, social workers, 
and non-pharmaceutical interventionists.  For this type of structural change to occur 
uniformly across the health care system; however, ambitious, long-term reforms will 
need to be made to payment systems.  Currently, Medicare, the largest insurer for people 
over 65 years of age, does not offer reimbursements that reflect the time and complexity 
of care needed by the families and individuals with dementia.  As a result, care providers 
are forced to make difficult decisions regarding patient care in order to balance financial 
obligations.  Changes to the current reimbursement system that recognize the challenges 
associated with treating dementia are necessary to ensure that providers are able to 
deliver the most appropriate care to patients and caregivers. 
Incentives should also be developed that reward health care organizations for 
delivering more comprehensive care at early stages of dementia.  Health care 
organizations that do not bear the cost of long-term care or institutionalization have no 
financial incentive to increase the quality of care early in the disease process, when 
treatment strategies can be more offensive and less reactionary.  Creating a financial 
incentive to identify patients with dementia and begin early comprehensive treatment will 
likely play a role in reducing psychotropic medication and also may also reduce costs by 
delaying institutionalization (41). 
The challenges facing informal dementia caregivers and physicians are enormous.  
The current treatment approach for mood and behavioral disturbances in dementia is 
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primarily pharmaceutical-based and highlights an opportunity to improve the way the 
patients with dementia and their informal caregivers are treated.  The dementia patient 
population is growing rapidly so it is imperative that the policies governing the delivery 
of care in the United States change quickly.  Our suggestions for reform include 
mandatory physician training on the management of dementia-related behavioral 
disturbances and the availability of local social assistance services, as primary care 
physicians are usually the first point of contact for dementia patients and their informal 
caregivers.  We also suggest taking the focus away from primary care physicians and 
directing it toward a multidisciplinary team including physicians and nurses with special 
training in gerontology, counselors, social workers, and non-pharmaceutical 
interventionists in order to address the needs to the dementia patient and the informal 
caregivers.  Finally, we recommend increases in health care reimbursements to providers 
to reflect the complexity of care needed to effectively treat dementia.  We also suggest 
that health care organizations be rewarded for providing comprehensive care as discussed 
above.  Without this change, people with dementia, particularly those exhibiting 
behavioral symptoms will be unnecessarily exposed to dangerous psychotropic 
medications. 
5.5 Final Comments 
Dementia is and will continue to be a significant public health problem.  Many 
patients with dementia are treated unnecessarily with dangerous psychotropic 
medications.  This dissertation expands current knowledge about psychotropic 
medication use in community-dwelling patients, a large but often over-looked segment of 
the dementia patient population.  Although this work represents only a small step forward 
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in understanding the relation between caregivers, care recipients, and medication use, we 
are providing the first evidence that care recipient pain and informal caregiver 
perceptions influence psychotropic medication use in community-dwelling dementia 
patients.  We also are the first group to identify that predictors of psychotropic 
medication vary over time and that there are important racial/ethnic disparities in 
medication use.  This dissertation has important implications for the development of 
interventions aimed at reducing psychotropic medication use in the community and also 
provides practical directions for future research and policy changes that will improve not 
only the lives of dementia patients and their caregivers, but other people struggling with 
chronic disease.  
  
155 
5.6 References 
1. Cummings JL,McPherson S: Neuropsychiatric assessment of Alzheimer's disease 
and related dementias. Aging (Milano) 2001; 13:240-246 
2. Maglione M, Ruelaz Maher A, Hu J, et al: Off-Label Use of Atypical 
Antipsychotics: An Update. Comparative Effectiveness Review No. 43. (Prepared by the 
Southern California Evidence-based Practice Center under Contract No. HHSA290-2007-
10062-1.), Rockville, MD, Agency for Healthcare Research and Quality, 2011 
3. Hanlon JT, Handler SM,Castle NG: Antidepressant prescribing in US nursing 
homes between 1996 and 2006 and its relationship to staffing patterns and use of other 
psychotropic medications. J Am Med Dir Assoc 2010; 11:320-324 
4. Kamble P, Chen H, Sherer JT, et al: Use of antipsychotics among elderly nursing 
home residents with dementia in the US: an analysis of National Survey Data. Drugs 
Aging 2009; 26:483-492 
5. Svarstad BL,Mount JK: Effects of Residents' Depression, Sleep, and Demand for 
Medication on Benzodiazepine Use in Nursing Homes. Psychiatr Serv 2002; 53:1159-
1165 
6. Weston AL, Weinstein AM, Barton C, et al: Potentially inappropriate medication 
use in older adults with mild cognitive impairment. J Gerontol A Biol Sci Med Sci 2010; 
65:318-321 
7. Jano E, Johnson M, Chen H, et al: Determinants of atypical antipsychotic use 
among antipsychotic users in community-dwelling elderly, 1996-2004. Curr Med Res 
Opin 2008; 24:709-716 
  
156 
8. Kunik ME, Snow AL, Davila JA, et al: Consequences of Aggressive Behavior in 
Patients With Dementia. J Neuropsychiatry Clin Neurosci 2010; 22:40-47 
9. Algase D, Beck C, Kolanowski A, et al: Need-driven dementia-compromised 
behavior: An alternative view of disruptive behavior. American Journal of Alzheimer's 
Disease 1996; 10-19 
10. Benedetti F, Arduino C, Vighetti S, et al: Pain reactivity in Alzheimer patients 
with different degrees of cognitive impairment and brain electrical activity deterioration. 
Pain 2004; 111:22-29 
11. Chan DC, Kasper JD, Black BS, et al: Clinical diagnosis of dementia, not 
presence of behavioral and psychological symptoms, is associated with psychotropic use 
in community-dwelling elders classified as having dementia. J Geriatr Psychiatry Neurol 
2007; 20:50-57 
12. Mittelman MS, Roth DL, Haley WE, et al: Effects of a caregiver intervention on 
negative caregiver appraisals of behavior problems in patients with Alzheimer's disease: 
results of a randomized trial. J Gerontol B Psychol Sci Soc Sci 2004; 59:P27-34 
13. Hernandez S, McClendon MJ, Zhou XH, et al: Pharmacological treatment of 
Alzheimer's disease: effect of race and demographic variables. J Alzheimers Dis 2010; 
19:665-672 
14. Mehta KM, Yin M, Resendez C, et al: Ethnic differences in acetylcholinesterase 
inhibitor use for Alzheimer disease. Neurology 2005; 65:159-162 
15. Poon I, Lal LS, Ford ME, et al: Racial/ethnic disparities in medication use among 
veterans with hypertension and dementia: a national cohort study. Ann Pharmacother 
2009; 43:185-193 
  
157 
16. Zuckerman IH, Ryder PT, Simoni-Wastila L, et al: Racial and ethnic disparities in 
the treatment of dementia among Medicare beneficiaries. J Gerontol B Psychol Sci Soc 
Sci 2008; 63:S328-333 
17. Blazer D, Hybels C, Simonsick E, et al: Sedative, hypnotic, and antianxiety 
medication use in an aging cohort over ten years: a racial comparison. J Am Geriatr Soc 
2000; 48:1073-1079 
18. Dealberto MJ, Seeman T, McAvay GJ, et al: Factors related to current and 
subsequent psychotropic drug use in an elderly cohort. J Clin Epidemiol 1997; 50:357-
364 
19. Hanlon JT, Fillenbaum GG, Burchett B, et al: Drug-use patterns among black and 
nonblack community-dwelling elderly. Ann Pharmacother 1992; 26:679-685 
20. Connell CM, Scott Roberts J, McLaughlin SJ, et al: Racial differences in 
knowledge and beliefs about Alzheimer disease. Alzheimer Dis Assoc Disord 2009; 
23:110-116 
21. Motsinger CD, Perron GA,Lacy TJ: Use of atypical antipsychotic drugs in 
patients with dementia. Am Fam Physician 2003; 67:2335-2340 
22. Aranda MP,Knight BG: The influence of ethnicity and culture on the caregiver 
stress and coping process: a sociocultural review and analysis. Gerontologist 1997; 
37:342-354 
23. Dilworth-Anderson P,Gibson BE: The Cultural Influence of Values, Norms, 
Meanings, and Perceptions in Understanding Dementia in Ethnic Minorities. Alzheimer 
Disease & Associated Disorders 2002; 16:S56-S63 
  
158 
24. Chaudhry I, Neelam K, Duddu V, et al: Ethnicity and psychopharmacology. 
Journal of Psychopharmacology 2008; 22:673-680 
25. Yeo G.,Gallagher-Thompson D. (eds): Ethnicity and the Dementias. New York, 
Routledge/Taylor Francis Group, 2006 
26. Anderson NB, Randy A. Bulatao,Cohen B (eds): Critical Perspectives on Racial 
and Ethnic Differences in Health in Late Life. Washington DC, The National Academies 
Press, 2004 
27. Dorsey ER, Rabbani A, Gallagher SA, et al: Impact of FDA black box advisory 
on antipsychotic medication use. Arch Intern Med 2010; 170:96-103 
28. Zarit SH, Orr NK,Zarit JM: The Hidden Victims of Alzheimer's Disease: Families 
Under Stress, New York, New York University Press, 1985 
29. Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: 
comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-
2314 
30. Pearlin LI, Mullan JT, Semple SJ, et al: Caregiving and the stress process: an 
overview of concepts and their measures. Gerontologist 1990; 30:583-594 
31. Jeste DV, Blazer D, Casey D, et al: ACNP White Paper: update on use of 
antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008; 
33:957-970 
32. Gill SS, Bronskill SE, Normand SL, et al: Antipsychotic drug use and mortality in 
older adults with dementia. Ann Intern Med 2007; 146:775-786 
  
159 
33. Schneeweiss S, Setoguchi S, Brookhart A, et al: Risk of death associated with the 
use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 
2007; 176:627-632 
34. Plassman BL, Langa KM, Fisher GG, et al: Prevalence of dementia in the United 
States: the aging, demographics, and memory study. Neuroepidemiology 2007; 29:125-
132 
35. Valle R,Lee B: Research Priorities in the Evolving Demographic Landscape of 
Alzheimer Disease and Associated Dementias. Alzheimer Disease & Associated 
Disorders 2002; 16 (Supplement 2):S64-S76 
36. Cox C,Monk A: Hispanic culture and family care of Alzheimer's patients. Health 
Soc Work 1993; 18:92-100 
37. Exner DV, Dries DL, Domanski MJ, et al: Lesser response to angiotensin-
converting-enzyme inhibitor therapy in black as compared with white patients with left 
ventricular dysfunction. N Engl J Med 2001; 344:1351-1357 
38. Yancy CW, Fowler MB, Colucci WS, et al: Race and the response to adrenergic 
blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001; 
344:1358-1365 
39. Wood AJ: Racial differences in the response to drugs--pointers to genetic 
differences. N Engl J Med 2001; 344:1394-1396 
40. Doody RS, Stevens JC, Beck C, et al: Practice parameter: management of 
dementia (an evidence-based review). Report of the Quality Standards Subcommittee of 
the American Academy of Neurology. Neurology 2001; 56:1154-1166 
  
160 
41. Hinton L, Franz CE, Reddy G, et al: Practice constraints, behavioral problems, 
and dementia care: primary care physicians' perspectives. J Gen Intern Med 2007; 
22:1487-1492 
 
 
